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Abstract: In this work, we identified the proteomics fingerprint of the anti-cancer drug 
candidate AUY922 in Jurkat leukemia cells and compared AUY922’s fingerprint  to the 
proteomics fingerprints of flagship Hsp90 inhibitors 17-DMAG and radicicol. Protein 
expression changes were identified by a label-free mass spectrometry technique, 
spectrum counting using a bottom-up proteomics approach. We identified 30 protein 
expression changes that were conserved among all the three Hsp90 inhibitors. To further 
validate findings from  spectrum counting assays and to identify more Hsp0 inhibitor-
induced protein expression changes, we quantified AUY922-induced and 17-DMAG-
induced protein expression changes by label-based Stable Isotope Labeling with Amino 
acids in Cell culture (SILAC) using a bottom-up proteomics approach. A total of 3000-
4000 inhibitor-induced protein expression changes were quantified. After statistical 
validation, 260 protein expression changes were found to be conserved among both the 
Hsp90 inhibitors. The large conservation of protein expression changes between 
AUY922 and 17-DMAG suggested that both inhibitors work via a similar mechanism. 
The protein expression changes common to AUY922 and 17-DMAG identified in this 
study can be used as biomarkers to test bioactivity of AUY922 in clinical trials and can 
also be used to validate new Hsp90 N-terminal inhibitors. Additionally, they can be 
compared to the proteomic fingerprints of agents that bind to the C-terminal domain of 
Hsp90, to determine if both classes of inhibitors share similar mechanisms of action. I 
also demonstrated that the anti-proliferative effects of AUY922 could be enhanced in 
combinatorial treatments with protein folding antagonist L-azetadine-2-carboxylic acid 
(AZC). I further used the SILAC approach to determine the mechanism of combinatorial 
effects of AUY922 and AZC and showed that the combinatorial effects were largely due 
to AZC-mediated suppression of chaperone induction. Thus, findings from this study 
suggest approaches for enhancing AUY922’s activity in clinical trials by using AUY922 
in combination with agents that suppress chaperone induction.
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Heat Shock Protein 90 (Hsp90) 
 
    Heat shock protein 90 (Hsp90) is arguably the most prominent of all the heat shock proteins. It is 
widely conserved across different domains of life (with the exception of archaea). In human beings, 
Hsp90 is the most abundant of all the Hsps, and constitutes about 1% of the total cellular protein. 
Hsp90’s isoforms play distinct biological roles in different cellular compartments. Cytoplasmic 
Hsp90 exists in two isoforms in mammalian cells, Hsp90α and Hsp90β. Hsp90β is constitutively 
expressed, whereas Hsp90α is heat or stress inducible. GRP94 and TRAP are the homologs of Hsp90 
in endoplasmic reticulum and mitochondria, respectively. 
 
Structure 
     Hsp90 has three domains: the N-terminal domain, the middle domain, and the C-terminal domain. 
X-ray crystallography studies have been used to understand the biological functions of each domain. 
Crystal structures of complexes between yeast Hsp90 and ATP/ADP have been produced [1] . This 
has led to the understanding that the N-terminal domain has a pocket for ATP binding. Hsp90 




   Hsp90’s middle domain harbors two important residues: Arg 380 and Gln 384, which are essential 
for Hsp90 ATPase activity. The middle domain also interacts with the client proteins [3]. The N-
terminal domain and the middle domain are connected to each other by a flexible linker.  
     The C-terminal domain is necessary for homo-dimerization. The C-terminal domain has a 
MEEVD sequence motif necessary for binding tetratricopeptide repeat-containing co-chaperone 
proteins. Several small molecule inhibitors also bind to this domain, here after called as C-terminal 
inhibitors [4]. Recently the C-terminal inhibitor site has been identified by protease fingerprinting, 
and by photo-affinity labeling followed by LC-MS/MS [5]. 
 
 Hsp90 function  
   Hsp90 is a molecular chaperone that folds proteins. Hsp90 folds proteins by undergoing a series of 
conformational changes. These conformational changes are driven by ATP binding and hydrolysis 
and are often referred to as the Hsp90 reaction cycle. Hsp90 exists as an open dimer in its free state. 
When ATP binds in the N-terminal pocket, the Hsp90 dimer undergoes structural transitions and 
acquires a closed conformation. This conformation allows the nascent polypeptides to be folded into 
their native conformations. Upon ATP hydrolysis and ADP release, Hsp90 is restored back to its open 
conformation. In the open conformation, the folded client proteins are released from Hsp90 [6].     
    Hsp90 functions in co-operation with a wide variety of other chaperones and co-chaperones. All 
these together constitute the Hsp90 chaperone machinery [7]. Co-chaperones play important roles in 
regulating Hsp90’s activity. A majority of the Hsp90 co-chaperones have TPR domains (examples: 
Hop, Chip and Tom70), and bind to the MEEVD motif in the C-terminal domain of Hsp90 [7]. Co-
chaperones assist Hsp90 by regulating it’s interactions with other chaperones, by stimulating or 
inhibiting ATPase activity, or by recruiting Hsp90 clients. Among the co-chaperones that modulate 
3 
 
ATPase activity of Hsp90, Aha1 and Crp6 stimulate the ATPase activity whereas Hop, Cdc37 and 
p23 inhibit the ATPase activity [8].  
Hsp90 Clients 
   The proteins that depend on Hsp90 for their conformation, stability, or activity are called Hsp90 
clients. To date, more than 200 proteins have been identified as Hsp90 clients, and the list is 
expanding. There are three major classes of Hsp90 clients: kinases, steroid hormone receptors and 
others that are not typically considered to be signal transduction proteins. Several steroid hormone 
receptors, including estrogen, androgen progesterone, and glucocorticoid receptors are known Hsp90 
clients [9, 10]. A wide variety of kinases including tyrosine kinases [11]  and cyclin dependent 
protein kinases [12, 13] are also Hsp90 clients. Telomerase [14], helicases, cytoskeletal proteins and 
several metabolic enzymes are other known Hsp90 clients [15]. A comprehensive list of Hsp90 client 
proteins can be found at http://www.picard.ch.  
Hsp90 Inhibitors 
      Hsp90 can be inhibited by small molecule inhibitors. The benzoquinone ansamycin geldanamycin 
(Fig 1.1), hereafter called “GA” was the first compound identified to inhibit Hsp90. GA reverts the 
Src tyrosine kinase mediated oncogenic transformation of NIH 3T3 cells by binding to Hsp90 and 
inhibiting its function [16]. Several years later, the macrocyclic anti-fungal antibiotic radicicol (Fig 
1.2) was also shown to inhibit Hsp90. Radicicol, like GA, suppresses oncogenic transformation by 
inhibiting the function of Hsp90 [17] . GA and radicicol act as Hsp90 inhibitors by binding to the 
ATP binding pocket in the N-terminal domain of Hsp90, and interfering with its ATPase cycle [18] . 
Thus these compounds are classified as N-terminal Hsp90 inhibitors.  
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      Figure 1.1 - Geldanamycin               Figure 1.2 - Radicicol 
                                                           
                                                       Images from Wikipedia Commons 
 
   GA showed good anti-cancer effects in cancer cell lines and animal models. But it was poorly 
soluble, lacked stability and was toxic. Therefore, it was not used for clinical purposes. Instead, 
derivatives of GA (17-Dimethylaminoethylamino-17-demethoxygeldanamycin, hereafter called 17-
DMAG, and 17-N-allylamino-17-demethoxygeldanamycin, 17-AAG) were developed. In 17-DMAG, 
the C-17 methoxy group of GA was replaced by N-N-dimethylamine. Compared to GA, 17-DMAG 
had better solubility and entered phase I trials. However, it was discontinued due to toxicity 
(clinicaltrials.gov). Radicicol was never considered for clinical trials due to toxicity and absence of 
activity in vivo [19].  
     Several other Hsp90 inhibitors were developed by various approaches. Currently 13 different 
Hsp90 inhibitors are in clinical trials. All these inhibitors can be divided into three types depending 
on similarity to geldanamycin (IPT-504), radicicol (AUY922), or an adenosine like scaffold. 
 
AUY922 
     AUY922 is a small molecule Hsp90 inhibitor. AUY922 belongs to the resorcinylic isoxazole 




exhibits high affinity for Hsp90 ATP binding pocket with an IC50 of 21 nM. Like other Hsp90 N-
terminal inhibitors, AUY922 also binds to the ATP binding pocket in the N-terminal domain of 
Hsp90 [20]. AUY922 depletes a wide variety of known Hsp90 clients and exerts potent anti-cancer 
effects in wide variety of cell lines and tumors at low nano-molar doses [21-26] . AUY922 exhibits 
cytostatic effects by arresting cells in G1/S or G2/M phase of the cell cycle [24]. Hence, AUY922 is 
considered as a promising candidate for cancer treatment. Currently, AUY922 is in Phase II clinical 
trials. 
                                                                 
Figure 1.3 - AUY922 (Wikipedia commons) 
In addition to Hsp90 N-terminal inhibitors, there are several small molecules that bind to the Hsp90 
C-terminal domain. Novobiocin is a coumarin antibiotic. It was the first compound that was identified 
to bind to the C-terminus of Hsp90. Similar to novobiocin, the coumarin antibiotics chlorobiocin and 
coumermycin A1 also bind to the Hsp90 c-terminal domain. All these compounds deplete known  
Hsp90 clients proteins such as erbB2, Raf-1 and p53 in cultured breast cancer cells [4]. However, 
unlike N-terminal inhibitors, they do not up-regulate Hsp70. Cisplatin also binds to Hsp90’s C-
terminal domain, and inhibits its activity [27] . EGCG, a green tea ingredient, also depletes Hsp90 
clients, including telomerase and several kinases [28]. Dr. Brian Blagg (Kansas University) has 
synthesized other structurally related C-terminal inhibitors that have anti-cancer activities in vitro 
[29-31]. The novobiocin and chlorobiocin binding sites in the Hsp90 C-terminal domain were 




Uses of Hsp90 inhibitors 
    The biological roles of Hsp90 have been elucidated by using Hsp90 inhibitors as tools.  
Hsp90 plays important roles in cancer by supporting mutant tyrosine kinases like Src [16]  and mutant 
p53 [32]. These Hsp90 roles were elucidated using geldanamycin. Since then, proteins involved in the 
six hallmark traits of cancer [33]  including receptor tyrosine kinases (EGFR), serine threonine 
kinases (Raf1 and Akt) [34], HIF1α [35]  and MMP2 [36] have been identified as Hsp90 clients by 
using Hsp90 inhibitors as tools. 
     Using Hsp90 inhibitors as tools, several Hsp90 dependent proteins have been identified [17, 37-
40] . These discoveries include steroid hormone receptors, kinases, and transcription factors. 
Identifications of steroid hormone receptors, kinases and transcription factors as Hsp90 clients led to 
highlight Hsp90’s role in steroid signaling, signal transduction, transcription, and immune responses. 
Other proteins such as Hsf1, calcineurin and nitric oxide synthase have also been identified as Hsp90 
clients, thus implicating Hsp90’s roles in heat shock response, calcium signaling and  nitric oxide 
signaling [7].  
     Hsp90 inhibitors are considered as promising candidates for cancer treatment. Hsp90 inhibitors 
attack  multiple oncogenic pathways simultaneously [41]. One model predicts that the selectively 
tumoricidal activity of Hsp90 inhibitors is due high affinity confirmation of Hsp90 in cancer cells [42, 
43]. However, this model has been questioned by Haystead et al. [44]. Nevertheless, the fact that 
Hsp90 inhibitors accumulate at a high rate in cancer cells compared to normal cells remains [42]. 
Additionally, Hsp90 inhibitors result in the depletion of proteins involved in all six hallmark traits of 
cancer [45]. Owing to these properties, Hsp90 inhibitors are considered to be viable candidates for 
cancer treatment.  
       Hsp90 inhibitors are also considered for the treatment of neurodegenerative disorders. 
Neurodegenerative diseases like Alzheimer’s and Parkinson’s are caused due to the accumulation of 
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toxic protein aggregates. Hsp90 inhibitors are predicted to ameliorate protein aggregates by inducing 
chaperones through the HSF1 mediated heat shock response [46]. 
 
Consequences of Hsp90 Inhibition 
   Hsp90 inhibition leads to the degradation of Hsp90-dependent client proteins. By inhibiting Hsp90 
from cycling through the chaperone cycle, client protein folding is compromised, resulting in their 
degradation. According to one prominent model, inhibitor-bound Hsp90 recruits CHIP (carboxy-
terminus of Hsp70 interacting protein), an E3 ubiquitin ligase, leading to the ubiquitylation of Hsp90 
client proteins and their subsequent degradation through the proteasome [47]. Attempts to study the 
global effects of Hsp90 inhibitors using proteomics approaches are discussed below. 
     Other major consequence of Hsp90 inhibition is activation of the heat shock response (HSR). The 
HSR is a signaling pathway involved in regulating protein homeostasis or proteostasis during stress 
conditions (discussed in more detail below). Inhibition of Hsp90 by small molecule inhibitors 
compromises Hsp90’s function. In one model, functionally compromised Hsp90 can no longer bind 
Hsf1 and as a result Hsf1 gets activated. Activated Hsf1 then initiates the heat shock response by 
acting as a transcription factor. In vitro, in an activation lysate model system, geldanamycin was 
reported to compromise Hsp90’s function and activate Hsf1 [48]. However, this model is not 
universally accepted. As pointed out by Shamovsky et al. [49] : “Despite numerous studies and 
extensive characterization, no defined in vitro system has been developed that reproduces Hsp90-
mediated repression of HSF in vitro.” In transformed fibroblasts, geldanamycin treatment results in 
increase in the levels of Hsps and this was shown to be mediated by Hsf1 activation [50]. In primary 
mouse skeletal myoblasts, two distinct Hsp90 inhibitors 17-AAG and AUY922 induce the expression 
of Hsp70, a consequence of Hsf1 activation [51]. There are two explanations for the activation of 
Hsf1 by Hsp90 inhibitors. According to one explanation, Hsp90 inhibitors cause bonafide  
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proteotoxic stress and result in the activation of Hsf1. According to the other explanation, Hsp90 
inhibitors activate Hsf1 by inhibiting Hsp90 and interfering with Hsp90 mediated repression of Hsf1. 
 
Proteomics of Hsp90 inhibition 
     Prior to 2012, four different studies described the effects of Hsp90 inhibitors at the proteome level 
(see the 2012 review by Hartson and Matts [15]). All these studies were done utilizing mass 
spectrometry approaches. The effects of 17-AAG on the proteome of A2780 ovarian cancer cells 
were reported in 2007 using 2D gel electrophoresis followed by MALDI-TOF mass spectrometry. In 
this study, 42 proteins including chaperones, mini chromosome maintenance (MCM) proteins, 
histones and other proteins involved in post-translational modifications were found to be altered upon 
Hsp90 inhibition [52]. Later in the same year, proteome wide effects of GA in anaplastic large cell 
lymphoma cells were reported using cICAT-LC-MS/MS approach. In this study, expression of 176 
proteins was found to altered by GA treatment. Proteins involved in the 26S proteasome were found 
to be up-regulated and proteins involved in signal transduction and protein and nucleic acid 
metabolism were found to be down-regulated [53]. In 2008, effects of radicicol on the ubiquitination 
of Hsp90 dependent proteins were reported in Hela cells using 2D gel electrophoresis followed by 
LS-MS/MS. This study identified several proteins involved in metabolism, gene transcription and 
signal transduction to be ubiquitinated upon Hsp90 inhibition, thus suggesting the Hsp90’s role in 
regulating these processes [54]. In 2008, effects of IPI-504 on the proteome of a pancreatic cancer 
cell line were studied using the ITRAQ (isobaric tags for relative and absolute quantitation) 
technique. In this study, 20 proteins were found to be down-regulated and 40 proteins were found to 
be up-regulated upon Hsp90 inhibition. Proteins involved in signal transduction, transport and 
metabolism were found to be altered [55].  
      In 2011/2012, two groups reported the global proteome-wide changes induced by Hsp90 
inhibitors. The first study published in late 2011, reported the global effects of 17-DMAG on the 
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proteome of HeLa cells using the SILAC approach. In this study, 7,000 proteins were identified and 
6,000 proteins were quantified. Within the major class of proteins up-regulated were proteases and 
heat shock proteins and among the down-regulated were kinases and DNA damage response proteins 
[56]. In 2012, another landmark study reported the proteome-wide changes induced by geldanamycin 
in four different cancer cell lines using SILAC approach. More than 6,200 proteins were identified in 
all the four cell lines and 1,600 proteins showed significant changes in protein expression. This study 
confirmed that Hsp90 inhibition mainly results in to the up-regulation of proteins involved in the 
stress response and down-regulation of kinases [57].  
     This thesis also utilizes SILAC similar to the studies above. This work will be compared to the 
SILAC studies above and will be presented in detail in the discussion section of chapter III. We will 
also cross reference our work to the older studies. 
 
Proteostasis 
      Protein homeostasis (“proteostasis”) describes the concept that living cells have biological 
pathways that work together to preserve the biological functions of proteins under diverse growth 
conditions. These major signaling pathways are the heat shock response (HSR) pathway, the 
endoplasmic reticulum associated degradation (ERAD) pathway, the unfolded protein response 
(UPR) pathway, and the ubiquitin-proteasome system (UPS). These signaling pathways maintain 
proteostasis in distinct sub-cellular compartments. A wide variety of heat shock proteins are key 
components of these pathways, and help to regulate proteostasis by ensuring proper protein folding, 
by preventing aggregation of misfolded proteins and sending misfolded proteins for degradation [58, 
59]. 
The Heat Shock Response (HSR) 
         The heat shock response (HSR) is a proteostasis signaling pathway activated upon heat stress. It 
protects living cells from heat stress or proteotoxic stress by inducing the expression of heat shock 
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proteins. Accumulation of unfolded proteins in a stressed cell prompts activation of the HSR. The 
HSR is regulated by heat shock factor 1 (Hsf1). Hsf1 is a transcription factor. According to one 
model, the activity of HSF1 is regulated by the Hsp90 chaperone complex. As per this model, Hsf11 
exists in an inactive state under non-stress conditions. The Hsp90 chaperone complex binds to Hsf1 
and keeps it in an inactive state. In its inactive state, Hsf1 is prevented from binding to genomic 
DNA. When unfolded proteins accumulate, they titrate Hsp90 from binding to Hsf1. As a result, 
Hsp90-bound inactive Hsf1 is released from Hsp90 and gets activated [60-62]. Activated Hsf1 then 
acts as a transcription factor to regulate the expression of a wide variety of genes, including Hsp 
genes [63]. Increased Hsp then regulates proteostasis by folding denatured proteins, by preventing 
aggregation of unfolded proteins, or by sending the unfolded proteins for degradation. Alternatively, 
Hsp90 inhibition leads to the activation of Hsf1, a topic discussed in detail in other sections of the 
thesis. 
The unfolded protein response (UPR) 
   The unfolded protein response (UPR) is another major stress response pathway that is activated by 
the ER stress. ER is the organelle where secretory and membrane proteins are synthesized and folded 
into their native conformations. Protein folding in ER is mediated by ER chaperones GRP78, GRP94, 
calnexin and calreticulin, and Hsp47. Any compromise in protein folding in the ER (e.g. defects in 
glycosylation, excessive protein folding burdens caused by stress, or chaperone inhibition, or 
alterations in disulfide bond formation) results in ER stress.  
      Living cells have signaling networks to detect ER stress and respond accordingly. These signaling 
networks collectively control the UPR. During UPR, protein synthesis in the ER is temporarily halted 
and expression of the ER chaperones is increased to cope with the protein folding burdens. 
      The UPR is regulated by three ER transmembrane proteins. They are PKR- like endoplasmic 
reticulum kinase (PERK), activating transcription factor (ATF6), and inositol-requiring protein 1 
(IRE1) [64]. The role of the PERK branch of the UPR is to regulate translation during accumulation 
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of unfolded proteins. The role of the ATF6 branch of the UPR is to up-regulate pro-survival genes in 
response to stress. IRE1 plays an essential role in UPR by transducing pro-survival and pro-apoptotic 
signals. 
   The activity of PERK, ATF6 and IRE1 are regulated by ER chaperone Grp78. Under normal 
conditions Grp78 binds to PERK, ATF6 and IRE1 and prevents them from being active. 
Accumulation of misfolded proteins in the ER leads to the dissociation of Grp78 from PERK, ATF6, 
and IRE1. Grp78 dissociates from PERK, ATF6, and IRE1 in order to bind the exposed hydrophobic 
residues on the unfolded proteins and to fold them back to their native conformations. Once released 
from Grp78, PERK, ATF6, and IRE1 become activated [64].  
 
Endoplasmic reticulum associated degradation (ERAD) 
  The endoplasmic reticulum associated degradation pathway (ERAD) is a major quality control 
program in the endoplasmic reticulum (ER). ERAD is a response to overburden in the ER. During 
stress, unfolded proteins accumulate in the ER. These unfolded proteins can be refolded into their 
native conformations by the ER chaperones, or, they can be degraded via the ERAD pathway based 
on the status of “mannose trimming” [65]. Mannose trimmed proteins are subjected to degradation via 
the ERAD pathway. Degradation of misfolded proteins by the ERAD pathway is accomplished in 
three steps: (i) recognition of the misfolded proteins in the ER; (ii) transport of the misfolded proteins 
to the cytoplasm; and (iii) degradation of the proteins by the ubiquitin dependent proteasome system 
in the cytoplasm.  Alternatively, an imbalance between folding capability and the protein folding 
burden in the ER can activate the unfolded protein response [64]. 
 
The ubiquitin proteasome system (UPS) 
   Ubiquitination is a protein post-translational modification by which proteins are tagged with a small 
protein called ubiquitin. Ubiquitination of proteins takes place in the following steps: (i) activation of 
12 
 
ubiquitin by an E1 ubiquitin activating enzyme; (ii) transfer of activated ubiquitin to an E2 ubiquitin 
conjugating enzyme, and finally, (iii) tagging of the target protein with ubiquitin (where a bond is 
formed between the C-terminal glycine of ubiquitin and lysine of a protein) which is mediated by the 
E3 ubiquitin ligases. Proteins can be ubiquitinated on a single lysine by one ubiquitin (mono-
ubiquitination) or by several ubiquitins (poly-ubiquitination), or they can be ubiquitinated on several 
lysines (multi-ubiquitination). The ubiquitination pattern ultimately decides the fate of the substrates, 
with poly-ubiquitination serving as a tag for protein degradation (discussed below). 
  The ubiquitin proteasome system (UPS) is another mechanism for regulating proteostasis. When 
unfolded proteins accumulate in the cell, the UPS helps regulate homeostasis by subjecting these 
proteins to degradation. Protein are degraded via UPS in two steps: (i) proteins are tagged with 
multiple molecules of ubiquitin to form polyubiquitin chains, and; (ii) poly-ubiquitinated proteins are 
degraded by the 26S proteasome machinery [66]. 
        Ubiquitinated proteins are degraded by the 26S proteasome. The 26 S proteasome is a large 
molecular machine made up of multiple subunits. It consists of a core complex (the 20S proteasome) 
which is capped on both sides by the 19S regulatory complexes. The regulatory complexes recognize 
and unfold the ubiquitinated proteins, and translocate them to the core of the complex for degradation. 
The proteolytic core complex degrades the ubiquitinated proteins [67]. 
 
Translational control of proteostasis 
   “Nascent polypeptide associated complex” (NAC) helps maintain proteostasis by regulating 
translation. NAC is a ribosome associated chaperone complex [68]. NAC folds ribosomal proteins 
and helps to regulate translation during normal conditions. When unfolded proteins accumulate in the 
cells, NAC dissociates from the ribosomes and prevents the aggregation of misfolded proteins by 
acting as a molecular chaperone. However when NAC is no longer associated with ribosomes, 
13 
 
translation is halted. Thus, NAC acts as a stress sensor, and helps to regulate translation during 
protein folding burdens [69]. 
 
Hsp90 inhibitors and activation of proteostasis pathways 
    Proteostasis pathways are activated by Hsp90 inhibitors. HSR is activated by the Hsp90 inhibitors 
17-AAG and radicicol through HSF1 mediated up-regulation of Hsps [50]. Similarly, HSR is induced 
by another Hsp90 inhibitor AUY922 through activation of the HSF1 pathway [51]. Apart from the 
HSR, the UPR is also activated by Hsp90 inhibitors. IRE1 mediated UPR is activated by 
geldanamycin [70]. The ATF6 branch of UPR is activated by 17-AAG and radicicol [71, 72] .  ER 
stress mediated UPR is also activated by Hsp90 inhibitors. GA and 17-AAG inhibit Grp94 (ER 
homologue of cytoplasmic Hsp90) and cause ER stress [73]. 17-AAG and PU-H71 induce the up-
regulation of ER chaperones GRP78 and GRP94 [71, 74]. PU-H71 also generates ER stress and 
results in UPR in different human cancer cell lines [74].  
 





     Tunicamycin induces ER stress and activates the UPR. Tunicamycin is produced by several 
bacteria from the Streptomyces family. Tunicamycin inhibits N-acetyl glucosamine transferases. This 
compromises N-linked glycosylation of proteins in the ER. These proteins cannot be properly 
processed and secreted, and thus they accumulate in ER. This results in protein folding burden, and 
leads to the activation of the UPR signaling pathway. 
    Tunicamycin induces the expression of ER chaperones. In mouse models and SILAC-based 
quantitative analysis, TM activates the UPR by up-regulating ER chaperone Grp78 [75]. Additionally 
SILAC-based studies also showed that tunicamycin up-regulates other ER chaperones cyclophilins B, 
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DnaJ homolog subfamily B member 11, endoplasmin, hypoxia up-regulated protein 1, protein 
disulfide isomerase, and protein disulfide isomerase A4 [76]. 
   Tunicamycin does not induce the expression of Hsp70. Although tunicamycin induces the 
expression of the ER chaperones GRP78 and GRP94, the expression of Hsp70 is unaltered by 
tunicamycin [77] . Since Hsp70 induction is a hallmark of HSR activation, this suggests that 
tunicamycin specifically activates the UPR but not the HSR. These results are consistent with 
previous findings that the expression of Hsp70 is not altered during the activation of the UPR by 
tunicamycin [77, 78] . This is an example of strict compartamentalization of the proteostasis 
pathways.           
L-Azetadine-2-carboxylic acid (AZC) 
   L-Azetadine-2-carboxylic acid (AZC) is a protein folding antagonist. AZC is a plant product found 
in members of Ruscaceae and Fabaceae. It is an analog of proline. However, it differs from proline, in 
that AZC has four-membered ring instead of proline’s five-membered ring. During protein synthesis, 
AZC can be incorporated into proteins instead of proline. This interferes with folding of those 
proteins [79]. As a result, unfolded proteins accumulate in the cell, thus leading to protein folding 
burdens. 
     The protein folding burdens caused by AZC leads to the activation of proteostasis signaling 
pathways. Although AZC’s activation of proteostasis signaling pathways is not well explored, some 
studies suggest its role in activating these pathways. Compromise of protein folding by AZC  
incorporation in S. cerevesiae leads to the activation of the Hsf1-mediated HSR and results in 27-fold 
induction in the expression of several HSF-regulated Hsp genes [80]. In addition, AZC induces ER 
stress and activates UPR in human HepG2 cells as evidenced by the induction of asparagine 
synthetase, a marker for UPR activation [81]. AZC also activates IRE1thus triggering kinases 




Mass spectrometry and proteomics 
Role of mass spectrometry and proteomics in systems biology 
    Systems biology is a discipline that deals with understanding the biology of living cells at the 
systems level. Systems biology gives insights on the cellular networks and their integrated roles in 
living cells. In order to understand how living systems work as a whole at the protein level, it is 
important to understand changes in protein expression under different conditions. Proteomics is a 
branch of systems biology that deals with studying the whole set of proteins under different 
conditions. Mass spectrometry is a technique used to perform large scale proteomics. With the 
advancement of instrumentation, separation techniques and software available to analyze the data, 
mass spectrometry has been a powerful tool to study systems-level changes in the expression of 
proteins under different conditions. 
Targeted proteomics 
    Targeted proteomics deals with studying a selected list of proteins rather than studying all proteins 
in the whole sample. In targeted proteomics, specific peptides from a selected protein are monitored 
by the mass spectrometer. Triple quad mass spectrometers are routinely used for targeted proteomics. 
In the first quadrupole ions of specific mass are selected for fragmentation and in the third 
quadrupole, ions of specific mass are selected for detection. This process in which selected ions are 
monitored is called selected reaction monitoring (SRM) or multiple reaction monitoring (MRM). 
 
Top-down and bottom-up proteomics 
     Proteomics experiments can be performed by two approaches: top-down or bottom-up. In top-
down proteomics, mass spectrometry is performed on intact proteins. The top-down approach starts 
with the separation of proteins, followed by their fragmentation and measurement of the masses of the 
precursor ion (intact peptide before fragmentation) and the fragment ions (ions resulting from the 
fragmentation of the precursor ions).  
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    In the bottom-up approach, purified proteins or complex mixture of proteins are enzymatically 
digested into peptides, the masses of the peptides are measured by mass spectrometry, and proteins 
are identified from the MS information obtained.  
 
Principles and instrumentation of mass spectrometry 
Ionization techniques 
       Mass spectrometers measure the masses of ionized molecules in a gas phase. The basic 
components of a mass spectrometer are the ion-source, the mass analyzer and the detector. For 
mass spectrometry analysis, molecules are ionized. Mass spectrometers work by using electric or 
magnetic fields to exert forces on ionized molecules. Therefore, for mass spectrometry analysis, 
molecules must be ionized (charged).  
  In proteomics, two soft ionization techniques are used to prevent fragmentation: Electrospray 
ionization (ESI) [83] and Matrix Assisted Laser Desorption and Ionization (MALDI) [84]. 
Electrospray ionization is used for ionization of the samples in liquid phase, and is thus is typically 
coupled to liquid chromatography (LC-MS). In MALDI, samples are embedded in a crystalline 
matrix, hence “off line”. 
  Electrospray ionization works by converting the liquid carrying the analytes of interest to a fine 
aerosol and ionizing the molecules by solvent evaporation. To facilitate solvent evaporation and thus 
ionization, volatile compounds like acetonitrile are used in the solvents. Organic acids like formic 
acid or acetic acid are added to the solvents to increase the conductivity and reduce the size of the 
initial droplet. Organic acids also donate protons and facilitate the ionization process. 
 
Mass analyzers 
   The mass analyzer is the heart of a mass spectrometer. Mass analyzers measure the mass-to-charge 
ratios (m/z) of ionized sample molecules. The key features of a mass analyzer are sensitivity (the 
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ability to detect low abundant molecules), resolution (ability to pack ions into tight ion packets), and 
accuracy (difference between the measured mass of an ionized sample molecule versus its actual 
mass). The accuracy of a mass analyzer depends on its resolving power. The higher the resolving 
power of a mass analyzer, the higher is its mass accuracy. 
    Different types of mass analyzers are utilized for different proteomics experiments. The most 
popular are quadrupole, ion-trap, Orbitrap, time-of-flight (TOF), and Fourier transform ion cyclotron 
(FT-MS) mass analyzers. The Quadrupole mass analyzers are made up of four cylindrical rods 
arranged opposite to one another. The opposing rod pairs are electrically connected and voltage is 
applied to the each pair of rods in alternating fashion. Varying the applied voltage filters which ions 
in a continuous stream hit the detector. Quadrupole mass analyzers are very fast, but have relatively 
low mass accuracy. 
     Ion-trap mass analyzers are similar to quadrupole mass analyzers, but are capped at each end with 
electrodes to trap ions in stable trajectories (“electrostatic bottle”). Increasing voltage in the trapping 
field results in the ejection of these ions through a hole, and the ions hit the detector. Ion-trap mass 
analyzers are different from quadrupole mass analyzers in that they fill and filter ions rather than just 
filtering ions. The advantages of the ion-trap mass analyzers are their robustness, sensitivity and 
inexpensiveness. The main limitation of ion traps is that ions smaller than 1/3
rd
 of the parent ion are 
lost during MS/MS. Another disadvantage of ion-trap mass analyzers is low mass accuracy relative to 
Orbitrap and TOF mass analyzers.  
   The Orbitrap is another mass analyzer. It was invented by Makarov [85]. The Orbitrap mass 
analyzer consists of a central spindle electrode and outer barrel electrode. The Orbitrap mass analyzer 
determines the m/z values of ions based on the frequencies of the oscillations of the orbitally trapped 
ions in the electric field. The main strengths of the Orbitrap mass analyzer are its high mass resolution 
(up to 150 000), high mass accuracy (2-5ppm), and high dynamic range (greater than 10
3
) [85]. 
However the limitation of the Orbitrap mass analyzer is it is very slow. 
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      TOF mass analyzers measure the m/z by measuring the time it takes for ions to reach the detector 
from the ion source. The advantages of TOF mass analyzers are their very high speed and accuracy.  
    In Fourier transform ion cyclotron (FT-MS) mass analyzers, ions are trapped in an electromagnetic 
field. Applying an external magnetic field makes the ions move in circular orbits. The frequency with 
which the ions move is called the cyclotron frequency.  In FT-ICR, ion masses are obtained from their 
respective cyclotron frequencies. The advantages of FT-MS analyzers are their low femtomole 
sensitivity, high resolving power (800,000) and high mass accuracy. FT-ICR mass analyzers are good 
for top-down proteomics. 
Tandem mass spectrometry (MS/MS) 
   In tandem mass spectrometry (MS/MS), the m/z measurements are done in two sectors. In the first 
MS sector a precursor ion of specific m/z is selected from a mixture of ions. The selected precursor 
ion is subsequently fragmented by collision with neutral gas to generate product ions. In the second 
MS sector, the m/z values of the product ions are measured. In triple quadrupole mass spectrometers, 
all the above steps are sequentially performed in two physical sectors which are separated in space 
(“tandem in space” mass spectrometry). Whereas in ion trap mass spectrometers, all the above steps 
are sequentially performed, but in the same physical sector of the instrument (“tandem in time” mass 
spectrometry).  
 
Fragmentation techniques  
     In proteomics, proteins are identified based on the amino acid sequence information obtained by 
protein or peptide fragmentation. Depending on the site of cleavage of the peptide backbone, the ions 
generated are classified as a, b and c ions (if the ions contain the N-terminus of the peptide), or x, y 
and z ions (if the ions contain the C-terminus of the peptide). Three fragmentation techniques are 
commonly used for peptide fragmentation. They are the collision induced dissociation (CID), the 
electron capture dissociation (ECD) and the electron transfer dissociation (ETD). In the CID 
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fragmentation, the peptide ions are fragmented by acceleration to a high energy state and collision 
with molecules of a neutral gas like helium, nitrogen or argon. CID fragmentation favors the most 
labile bond, typically the peptide amide bond (C-N) to generate b and y ions. These can then be used 
for sequence determination and protein identification. In the ECD fragmentation, peptides are 
fragmented following capture of an electron by a multiply protonated peptide ion. The ECD 
fragmentation cleaves the backbone N–Cα bond and results in c and z ions. In the ETD 
fragmentation, peptides are fragmented in gas phase following transfer of an electron from anthracene 
or fluoranthene to a multiply protonated peptide ion. ETD fragmentation, similar to the ECD 
fragmentation cleaves the backbone N–Cα bond and yields c and z ions [86]. 
     In top-down proteomics, ions can be fragmented by ECD or ETD fragmentation. In ECD or ETD 
fragmentation, fragmentation of ions is random. This helps for good sequence coverage. Additionally 
in ECD/ETD fragmentation, post-translational modifications are not lost. Therefore top-down 
proteomics is good for identifying post-translational modifications. 
     In bottom-up proteomics, ions can be fragmented by CID fragmentation or by HCD 
fragmentation. In CID and HCD fragmentation, the fragmentation is biased to weakest bonds. As a 
result, post translational modifications are lost. Therefore, collisional dissociation is not suited for 
identifying post-translational modifications. Nevertheless, the bottom-up approach is routinely used 
for protein identification and quantitation. 
 
Quantitative proteomics techniques 
     Quantitative proteomics deals with quantitation of proteins in complex protein mixtures. 
Quantitative proteomics can be divided into two types: relative quantitative proteomics techniques 
and absolute quantitative proteomics techniques. In relative quantitative proteomics techniques, the 
relative abundance of proteins across two different samples is measured. There are two approaches 
for quantitation in relative quantitative proteomics. They are label-free and label-based. In label-free 
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approaches, isotope-labeled amino acids are not used, and samples from the two different 
experimental categories are analyzed separately. Two types of label-free approaches are used in label-
free quantitation: (i) ion intensity measurement and (ii) spectrum counting. In the ion intensity 
approach, MS peak areas from the chromatograms of two samples are compared. Using this 
information, differences in relative abundance of peptides between two samples is determined. In the 
spectrum counting approach, the abundance of proteins in the samples is assessed by counting 
number of MS/MS spectra associated with peptides from each protein. An increase in the number of 
MS/MS spectra from a given protein indicates more abundance of that protein and vice versa. 
      In label-based quantitative proteomics approaches, samples from two different experimental 
groups are labeled with stable isotopes that share exactly the same chemical properties, but differ by 
mass. Isotopic labeling can be done in-vitro by chemical labeling or in-vivo by metabolic labeling. 
Examples of  chemical labeling approaches are isotope coded affinity tags (ICAT) [87] and isobaric 
tags for relative and absolute quantitation (ITRAQ) [88]. ICAT labeling reagents have: (i) a reactive 
group that labels the thiol groups of cysteine, (ii) a linker that can be isotopically tagged and (iii) an 
affinity tag (biotin) which facilitates affinity purification. In ICAT, protein mixtures from two 
different experimental groups are tagged with light and heavy ICAT reagents, samples are mixed, 
digested, affinity purified, and then difference in protein expression across the experimental groups is 
quantified. In ITRAQ approach, peptides from different experimental samples are labeled with tags of 
different masses. The samples are then pooled and quantitative differences in protein expression 
across the groups are identified. Currently ITRAQ supports analyzing protein expression changes 
across 8 experimental groups (8-plex). 
     In the metabolic labeling approach, non-isotopic or isotopic lysine and arginine are metabolically 
incorporated into all proteins, (e.g. stable isotope labeling with amino acids in cell culture (SILAC)) 
by growing the cells in media supplemented with isotopic or non-isotopic amino acids [89]. The 
differentially tagged samples are then pooled, digested, chromatographically fractionated, and 
analyzed by mass spectrometry. In this approach, two populations of cells are grown in media 
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supplemented with the same components, except that one medium contains heavy isotopic amino 
acids and the other medium contains light isotopic amino acids. Cells grown in heavy and light media 
are used for studying proteins in two different conditions. For protein identification and quantitation, 
protein samples from both the cell populations are extracted, mixed and analyzed by mass 
spectrometry. Quantitation is performed by measuring the relative peak areas of heavy/light peptide 
pairs. SILAC offers several advantages over the label-free approaches: because different experimental 
samples are pooled and processed in the same way, there is less technical variability across 
experiments , and the time required to analyze the samples is reduced [90]. 
 
Bioinformatics tools for protein identification and quantitation 
    Several database search engines are available for identifying proteins from mass spectrometry data. 
Some commonly used search engines are SEQUEST, Mascot, OMSSA, X! Tandem and Andromeda. 
All these search engines work in a similar manner. They match theoretical versus experimental m/z’s 
and generate scores for each spectrum to find peptide or protein matches. These scores represent the 
strength of the match between observed and predicted MS/MS spectra. Most search engines use 
probabilistic scoring approaches. The probabilistic approach calculates the probability that the match 
between experimental data and each peptide/protein sequence occurs by chance. Mascot is a 
proteomics search engine that uses probabilistic approach for protein identifications [91]. X! 
TANDEM is an open source search engine [92]. It is used as a search engine by Scaffold. Andromeda 
is another search engine that uses probabilistic scoring model [93]. It is used as a search engine by 
MaxQuant. 
    Scaffold is another proteomics tool. In proteomics, there is a high probability of reporting false 
identifications. Scaffold validates the proteins identified by other database search engines. Scaffold 
employs Peptide Prophet and Protein Peptide algorithms to statistically validate results obtained from 
the search engines. These algorithms analyze populations of search engine scores. By comparing the 
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results obtained from the X! Tandem and other search engines, Scaffold gives increased confidence in 
the proteins identified in large datasets [94]. Scaffold Q+S is new version of Scaffold for quantitative 
analysis of SILAC data. It performs data normalization, quantitation, and statistical analysis of 
SILAC output data obtained from MaxQuant (discussed below).  
     MaxQuant is proteomics software developed by Cox and Mann at the Max-Planck Institute. It is 
used for the analysis of high resolution, quantitative mass spectrometry data obtained from SILAC 
experiments. MaxQuant quantifies thousands of SILAC peptide pairs by using a series of algorithms 
for peak detection, isotope cluster detection and SILAC pair detection. To accomplish this, MaxQuant 
uses correlation analysis and graph theory. For peak detection and quantification, MaxQuant uses 
mass and intensity of the peptide peaks. In order to do this, MaxQuant fits the points in each MS scan 
using Gaussian curve and thus identifies the 2D peaks in each MS scan. From the 2D peaks 
MaxQuant then assembles 3D hills. 3D hills are generated over m/z axis. Using centroid masses, 
MaxQuant then estimates 3D peak volume. Using this information, MaxQuant identifies and 
quantifies thousands of proteins [95].  
 
Bioinformatics programs for statistical analysis and processing of proteomics data 
Perseus 
     Perseus is a program used for analyzing quantitative proteomics data obtained from MaxQuant. It 
can be used for common functions such as data normalizations, calculations (log transformations, 
ratios, means, medians and other common calculations) and enrichments. It can also be used for 
creating plots and for small range of statistical analysis. One limitation of Perseus is that its code is 





Proteomics fingerprint of Hsp90 N-terminal inhibitors AUY922, 17-DMAG and 
radicicol using the spectrum counting approach 
 
Introduction 
    Although pharmacological compounds are designed to have specificity for a particular target 
protein, it is highly possible that they can target other proteins. These phenomena are called off-
target inhibitor effects. Targeting proteins other than the target protein may result in harmful side 
effects, or may prove to be beneficial in some cases. Also, structurally distinct inhibitors that are 
all designed to target a specific protein might have different phenotypic effects resulting from 
differences in their targets. Mechanisms of inhibitor action can be inferred from the phenotypic 
effects (reporters) that the inhibitor causes. 
    Several structurally distinct small molecule inhibitors bind to the Hsp90 N-terminus and inhibit 
its function. All these Hsp90 N-terminal binding agents lead to the indirect depletion of a wide 
variety of Hsp90-dependent proteins in vitro. However, in cultured cells how much of the anti-
proliferative effects of these N-terminal binding agents are specifically due to Hsp90 inhibition is 
not well known.  
     We wanted to address this question by studying the proteome-wide effects of structurally 
distinct Hsp90 N-terminal binding agents in cultured cancer cells and comparing their proteomics 
fingerprints. By doing so, we would expect to see conserved inhibitors effects if all these 
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inhibitors inhibit cell proliferation by inhibiting Hsp90. However, if a given inhibitor acts by off 
target effects we would expect to see proteome alterations unique to each inhibitor.  
    Dr. Brain Blagg’s laboratory at the University of Kansas has synthesized several small 
inhibitors that bind to the Hsp90 C-terminus and inhibit its function (hereafter called Hsp90 C-
terminal binding agents).These C-terminal binding agents bind Hsp90 C-terminal domain in vitro. 
Additionally, these C-terminal binding agents exhibit anti-proliferative effects in a wide variety 
of cancer cell lines and deplete several known Hsp90 clients. However, proteome-wide changes 
induced by the C-terminal binding agents are not reported. 
     Long term goals of our laboratory are to validate Hsp90 C-terminal binding agents using 
proteomics approaches. Identifying proteomics fingerprints of Hsp90 N-terminal binding agents 
will allow us to compare their effects to the effects of C-terminal binding agents. This will give 
insights into the mechanisms of action of the two classes of inhibitors and whether their 
mechanisms of action are conserved. Additionally, biomarkers of Hsp90 N-terminal binding 
agents identified in this study can be used to validate Hsp90 N-terminal binding agents in the 
clinic, and will also help to characterize novel Hsp90 N-terminal binding agents. 
       In this study, we characterized the effects of three structurally distinct Hsp90 N-terminal 
inhibitors AUY922, 17-DMAG and radicicol on the proteome of Jurkat leukemia cells. We 
quantified changes in protein expression by spectrum counting using a bottom-up proteomics 
approach. We present the proteomic fingerprints of three Hsp90 N-terminal binding agents and 
identify a small assortment of biomarkers for Hsp90 N-terminal inhibition. We also explore the 
limitations of the spectrum counting technique, and thus highlight the need for using superior 





Materials and Methods 
Reagents 
     Jurkat leukemia cell line E6.1 was obtained from American Type Culture Collection. SILAC 
RPMI medium was purchased from Thermo Scientific (Catalog number 89984). Amino acids L-
lysine-2Hcl (Catalog number 89987), L-aarginine-Hcl (Catalog number 89989) and 13C6 15N4 
L-aarginine (Catalog number 89990) were purchased from Thermo Scientific. Amino acid 13C6 
15N2 L-llysine (Catalog number 291-0.25) was purchased from Cambridge Isotopic Laboratories, 
Inc. Dialyzed fetal bovine serum (Catalog Number 89984) was purchased from Thermo 
Scientific. 17-DMAG, radicicol and AUY922 were obtained from LC Laboratories (Catalog 
Number D3440), Cayman Chemicals (Catalog Number 13089) and Selleck Chemicals (Catalog 
Number S1069), respectively. Hybri-Max DMSO (Catalog Number D2650) was obtained from 
Sigma. Inhibitors were dissolved in DMSO. L-azetadine-2-carboxylic acid (AZC) was obtained 
from Sigma (Catalog Number A0760) and dissolved in water. CellTiter Aqueous One Solution 
Cell Proliferation Assay (MTS) reagent was obtained from Promega (Catalog Number G3581). 
PVDF membrane was obtained from Bio-Rad. Mouse monoclonal anti-human β-actin antibodies 
were obtained from Sigma (Catalog number A5441). Rabbit polyclonal anti-human Poly-ADP 
ribose polymerase (PARP) antibodies were obtained from Cell Signaling Technology (Catalog 
Number 9542). Rabbit monoclonal anti-human Cdk6 (Catalog Number 3524-1), Cdk1(Catalog 
Number 3787-1), Dnmt1(Catalog Number 2788-1) and DDX5 antibodies (Catalog Number-5567-
1) were obtained from Epitomics, goat polyclonal anti-human UNR antibodies (Catalog Number 
sc-79293), rabbit polyclonal anti-human MCM7 antibodies (Catalog Number sc-22782) and 
mouse monoclonal anti-human UHRF1 antibodies (Catalog Number sc-166898) from Santa Cruz 
Biotechnology Inc., rabbit polyclonal anti-human eIF4A1 antibodies from Abcam (Catalog 
Number ab31217). SuperSignal West Pico Chemiluminiscent substrate (Catalog Number 34077) 
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was purchased from Thermo Scientific. 4-20% Mini-PROTEAN TGX precast gels were 
purchased from Bio-Rad (Catalog number 456-1094).L-Dithiothreotol (DTT) (Catalog number 
43819-1G) and Iodoacetamide (IAA) (Catalog number 16125-5G) were purchased from Sigma. 
General cell culture, cell proliferation assays and inhibitors treatments 
   Jurkat cells were cultured in RPMI media supplemented with 10% dialyzed fetal bovine serum, 
200 mM/ litre L-glutamine, light isotopic lysine (50 mg/ 500 ml) and arginine (50 mg/ 500 ml) 
amino acids, streptomycin (500 µg/ mL), penicillin (100 units/ mL). Cells were cultured at 37°C 
in a humidified 5% CO2 incubator. 
      For cell proliferation assays, cells were seeded in 96 well plates at a density of 10,000 cells/ 
100 µl/ well. After twenty four hours, cells were treated with a dilution series of each of the 
inhibitors 17-DMAG (1.6, 4.9, 14.8, 44.0, 133, 400, 1200, 3600 and 10,800 nM) , radicicol (0.8, 
2.3, 7, 21, 62, 185, 555, 1670 and 5000 nM) or NVP-AUY922 (1, 3.5, 11.5, 35, 100, 300 and 900 
nM). For control experiments, cells were treated with DMSO (solvent in which all the three 
inhibitors are dissolved). Following inhibitor treatment, cells were incubated at 37°C in a CO2 
incubator. Cell viability was determined  using Cell Titer Aqueous One Solution Cell 
Proliferation Assay(MTS) reagent from Promega (Inhibitors doses and duration are described for 
individual experiments). Twenty microliters of MTS reagent was added to the inhibitor treated or 
DMSO treated wells and the plates were incubated at 37°C in the CO2 incubator for 4 hours. 
Absorbance of the 96 well plates at 490nm was recorded using Molecular Devices Versamax 
plate reader. All experiments were performed in three biological replicates. 
     For determining the IC50 values for Cdk6 depletion, cells were seeded in 10 mL in T-25 cm
2
 
flasks. After twenty four hours, cells were treated with a dilution series of each of the 
inhibitors17-DMAG, radicicol or AUY922 (dilution series of each inhibitors used for IC50 
determinations are mentioned in the later sections of this chapter). For control experiments, cells 
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were treated with DMSO. Twenty four hours following inhibitor treatments, cells were harvested 
and lysates were prepared for Western blotting.  
Preparation of cell lysates and determination of protein concentration 
    Following inhibitor treatments, cells were harvested by 5 minute centrifugation at 1700rpm. 
Cell pellets were washed twice with phosphate buffered saline, pH 7.4. After washing, the cell 
pellets were lysed with radio immuno precipitation (RIPA) lysis buffer containing 20 mM sodium 
phosphate, 50 mM glycerophosphate, 100 mM sodium chloride, 0.1% SDS, 2% NP40, 0.75% 
deoxycholate, 5 mM EDTA, 5 mM EGTA, and 2 mM sodium orthovanadate, 10 mM NaF, 0.1 
mg/ml PMSF, 1 X Sigma protease inhibitor cocktail and 1mM DTT, at 4°C on a rocker. 
Following lysis, the lysates were clarified at 12,000 x g for 10 minutes. Protein concentrations in 
the lysates were determined by Bradford reagent using BSA as a standard. 
Determination of IC50 values for Cdk6 depletion 
   Twenty micrograms of untreated, DMSO treated, and inhibitor-treated cell lysates were boiled 
in SDS-PAGE buffer containing 100 mg/ ml DTT, and loaded onto an 8% polyacrylamide gel. 
Proteins were separated by running the gels at 25 mA. Post gel run, proteins were transferred onto 
a PVDF membrane and the membranes were probed with anti-Cdk6 antibodies. After incubation 
with secondary antibodies, the membranes were developed using standard chemiluminiscent 
techniques. All experiments were done in three biological replicates. IC50  values were determined 
using GraphPad Prism software. Data were fit using non-linear regression analysis (least squares 





Sample preparation for mass spectrometry 
    For LC-MS/MS analysis, proteins in the cell lysates were TCA/ acetone precipitated. Resulting 
protein  pellets were dissolved in buffered urea solution containing 8 M urea, 100 mM Tris-Hcl, 
pH 8.5 and reducing agent TCEP (tris (2-carboxyethyl)phosphine) at room temperature for 20 
minutes and alkylated with one tenth volume of 100 mM IAA (iodoacetamide) in dark, at room 
temperature for 15 minutes. Samples were further reduced with one twentieth volume of 100 mM 
DTT in the dark at room temperature for 5 minutes. Then the samples were diluted with 100 mM 
Tris-Hcl, and digested with a final concentration of 4 µg/ml trypsin for overnight at 37 degrees C. 
Trypsin digested samples were acidified with 2 µl of 100%TFA and desalted by using C18 
affinity tips (OMIX). Desalted samples were vacuum dried and stored at -80°C for subsequent 
LC-MS/MS analysis. 
LC-MS/MS analysis  
    LC-MS/MS analysis was done by running samples on Thermo Fisher Scientific hybrid LTQ-
Orbitrap mass spectrometer. A New Objective PV-550 nanoelectrospray ion source was used for 
electrospray ionization.  An Eksigent NanoLC-2D liquid chromatography system was used for 
separation of the peptides. Peptides were first trapped on a 2.5 cm pre-column with a vented 
column configuration (5-μm Magic C18 AQ). Trapping was done at high flow rates and was used 
to remove residual salts in the sample. Salts were disposed through waste and only peptides were 
allowed to flow though the analytical column. Trapped peptides were then separated on a 75 μm 
ID 15-cm fused silica column (5-μm Magic C18 AQ) terminated with an integral fused silica 
emitter. Peptides were eluted by using a 2.5-28% ACN/0.1% formic acid gradient over 116 min at 




Eluted peptide samples were ionized by nanospray. Instrument was operated in a data dependent 
scanning mode. Data dependent scanning mode allows for an automated choice for selecting 
specific ions for further MS/MS analysis. Full scan MS spectra for ions 360-1400 m/z were 
acquired in the Orbitrap with a nominal resolution of 60,000 FWHM. Full range lock-mass FT-
MS scan was enabled for real time calibration and for high accuracy measurements. The six most 
abundant peptides (top six) were selected for further fragmentation in the ion trap by using CID 
(collision induced dissociation) fragmentation. For MS/MS analysis, only intense ions (with ion-
intensity counts greater than 8,000) were chosen. To save instrument time and duty cycle only 
mono-isotopic precursors were selected for MS/MS analysis. Parent ions with unassigned charges 
were not chosen for further MS/MS analysis because the m/z values cannot be determined for 
these ions. Ions previously identified as contaminants and ions already selected for MS/MS 
analysis (dynamic exclusion at 150% of the observed chromatographic peak width) were also not 
chosen for further MS/MS analysis.  
Data analysis 
    MS spectra from the parent ions and MS/MS spectra (tandem spectrum) of the resulting 
daughter fragments were acquired and stored. Extract_msn_.exe utility from Bioworks 3.3.1 was 
used to extract the tandem mass spectra by converting the raw files into peak list files. Extracted 
MS/MS spectra were searched against a database which has tandem spectra of all known human 
proteins generated by in-silico digestion. Tandem mass spectra were searched against 
IPI.HUMAN.v3.87 database (91,464 protein entries) using Mascot (Matrix Science, London, UK; 
version 2.2.04) and X! Tandem (The GPM, thegpm.org; version 2007.0.1.01.1) with the 
assumption that trypsin was the enzyme used for in-silico digestion of the human proteins. 
Parameters used for Mascot and X! Tandem search were: fragment ion mass tolerance of 0.60 Da 
(i.e. the difference between observed mass and theoretical mass should be 0.6 Da) and parent ion 
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tolerance of 5.0 PPM, variable modifications specified were S-carbamoylmethylcysteine 
cyclization, n-Formylation of the N-terminus, acetylation of the N-terminus and iodoacetamide 
derivative of cysteine (telling the program there could be mass difference due to these 
modifications). 
Criteria used for protein identification 
   Scaffold version 3.6.5 (Proteome Software) was used to validate peptide and protein 
identifications using Scaffold’s Peptide prophet and protein prophet algorithms  and high mass 
accuracy scoring option. Protein identifications were based on 99% protein probability, 2 
minimum peptides, and 50% minimum peptide identification probability. Proteins that shared 
similar peptides but could not be differentiated based on MS/MS analysis alone were grouped to 
satisfy the principles of parsimony (i.e. reporting the minimum set of protein sequences that 
adequately account for all observed peptides). Databases searches also included searches against 
decoy database (database with reverse sequences) to estimate the incorrect protein identifications, 
i.e. false discovery rates (FDR). 
    The spectrum counting approach was used for quantitative analysis of changes in protein 
expression. Analysis was done by normalizing the data. Normalization was done assuming 
unequal sample load and/or variations in the sample processing. Scaffold’s normalization works 
by multiplying some fractional amount across samples so that the total spectra are same within 







     Before characterizing AUY922’s effects on the Jurkat cell proteome, we wanted to first 
establish the concentrations of AUY922 that inhibited 50% of the proliferation of Jurkat cultures 
(IC50). To accomplish this, we treated Jurkat cultures with the indicated doses of AUY922 and 
measured the effects on cell proliferation. Results showed that AUY922 caused anti-proliferative 
effects starting from 3.5 nM to 11.5 nM, inhibiting the proliferation of 25% of the cells. Beyond 
35 nM doses, AUY922 completely inhibited the proliferation of Jurkat cultures. At the 35 nM - 
900 nM dose range, cells maintained densities that were used during seeding. Therefore it was 
concluded that AUY922 exhibits cytostatic rather than cytotoxic effects.  We also identified that 
AUY922 inhibits the proliferation of Jurkat cultures at low nano-molar doses, with calculated 
IC50’s of 10.27 nM, 7.2 nM and 8.6 nM after 24 hours, 48 hours and 72 hour respectively (Fig 
2.1). This suggested that AUY922’s effects were stronger at 48 and 72 hours. Our results were 
consistent with previous reports that AUY922 inhibits the proliferation of several cancer cell lines 
at low nano-molar doses [26, 96, 97]  and exhibits cytostatic effects [24]. 
   Before characterizing the effects of Hsp90 inhibitors on Jurkat proteome, we wanted to identify 
a strong Hsp90 dependent reporter protein that can be best used to identify appropriate Hsp90 
inhibitor concentrations. Previous reports [98, 99] , and unpublished results from our lab, showed 
Cdk6 to be rapidly depleted and easily detectable upon Hsp90 inhibition. Therefore, we chose to 
test if Cdk6 is a sensitive reporter of Hsp90 inhibition. To accomplish this, we treated Jurkat 
cultures with classic Hsp90 inhibitor 17-DMAG and assayed the inhibitors’ effects on Cdk6 
depletion. Results showed the rapid depletion of Cdk6 after 8 hour treatment with 150 nM 17-





                                    
 
Figure 2.1: Effects of AUY922 on Jurkat cell proliferation. 
Jurkat cultures were incubated for 24, 48 or 72 hours with indicated concentrations of AUY922 
and cell proliferation was measured as described in methods. Each data point represents % 
proliferation relative to control. Error bars are the SEM (N=3). For the curve fits shown, the R
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Figure 2.2: Time course of Cdk6 depletion upon treatment with 150 nM 17-DMAG. 
Jurkat cultures were treated with 150 nM 17-DMAG and after 0, 2, 4 or 8 hours of treatment, 


















      After establishing Cdk6 as a sensitive reporter for Hsp90 inhibition, Cdk6 was used as a 
marker to identify the appropriate concentration of AUY922 that depletes Hsp90 dependent client 
proteins in cultured Jurkat cells. To accomplish this, Jurkat cells were treated for 24 hours with 
the indicated doses of AUY922 and assayed the inhibitor’s effects on Cdk6 levels. Results 
demonstrated a dose-dependent depletion of Cdk6 by AUY922 as shown in Figure 2.3A. Thus, 
we concluded that AUY922 lead to the depletion of Cdk6 with a calculated IC50 of 11 nM as 
shown in Figure 2.3B. For AUY922, the IC50 doses for Cdk6 depletion (11 nM) closely matched 
with the IC-50 doses for cell proliferation (10 nM). Our results were also consistent with previous 
reports showing Cdk6 depletion by AUY922 at 10 nM concentration in human gastric cancer cell 
line NCI-N87 [25].  
    To characterize the effects of AUY922 and other Hsp90 inhibitors on the Jurkat proteome, we 
first wanted to treat Jurkat cultures with appropriate doses of AUY922, but without grossly 
compromising cell viability. Thus, PARP cleavage was used as a marker for apoptosis. During 
apoptosis PARP is cleaved by caspases to yield two fragments of molecular weights 89 kDa and 
24 kDa [100, 101]. Therefore, Jurkat cultures were treated for 24 hours with the indicated doses 
of AUY922, and the inhibitor’s impacts on PARP cleavage were assessed. Results showed that at 
doses ranging from 1- 16 nM, AUY922 had negligible effects on PARP cleavage. At higher 
doses, AUY922 induced some PARP cleavage (Fig 2.4). Therefore, we conclude that the effects 
of AUY922 were largely sub-apoptotic at doses ranging below 1- 128 nM. 
      Before comparing AUY922’s effects on the Jurkat proteome to the effects caused by other 
Hsp90 inhibitors 17-DMAG and radicicol, we wanted to identify the appropriate doses of DMAG 
and radicicol for cell proliferation. We accomplished this, using the same approaches as described 
for AUY922 in the above sections. Results showed that 17-DMAG, similar to AUY922, exhibited 
cytostatic effects at high doses but had a less steep dose response curve compared to AUY922.  
However, radicicol unlike AUY922 and 17-DMAG, exhibited cytotoxic rather than 
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Figure 2.3: Dose-dependent depletion of Hsp90 dependent client protein Cdk6 by 
AUY922.  
Panel A: Jurkat cultures were incubated for 24 hours with indicated concentrations of AUY922 
and Cdk6 depletion was assessed by western blotting. Actin was used as a lane-loading control. 
Panel B: IC50 values for Cdk6 depletion were estimated by performing densitometry on 
independent biological experiments (N=3). Data were curve-fitted as described in methods. The 
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Figure 2.4: Apoptotic effects of AUY922 as assessed by PARP cleavage.  
Jurkat cultures were treated for 24 hours with the indicated doses of AUY922. After 24 hours, 

















cytostatic effects and the dose response curve was less steep compared to AUY922 and 17-
DMAG (Fig 2.5, Panel B). 17-DMAG and radicicol inhibit the proliferation of Jurkat cells with 
IC50 values as shown in the Table 2.1 below. Therefore, we conclude that both 17-DMAG and 
radicicol inhibit the proliferation of Jurkat cultures, but with less potency compared to AUY922. 
   Similarly, we determined the IC50 values for 17-DMAG and radicicol for Cdk6 depletion as 
described for AUY922 in the above sections. Results showed a dose-dependent depletion of Cdk6 
by both inhibitors (Fig 2.6, Panel A & Fig 2.7, Panel A), with calculated IC50 values of  30 nM for 
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Figure 2.5: Effects of 17-DMAG (5a) and radicicol (5b) on Jurkat cell proliferation. 
Jurkat cultures were incubated for 24, 48 or 72 hours with the indicated concentrations of 
17-DMAG (Panel A) and radicicol (Panel B), after which cell proliferation was measured 
as described in methods. Each data point represents proliferation relative to control. Error 
bars are the SEM (N=3). For the curve fits shown, the R
2
 values for 17-DMAG were 
0.9575, 0.9685 and 0.9690 for 24, 48 and 72 hours respectively, and the R
2
 values for 




Table 2.1: IC50 values for cell proliferation for AUY922, 17-DMAG and radicicol.  
 
 
AUY-922 17-DMAG Radicicol 
IC-50 
values 
24 hours- 11.2 ± 4.47 nM 
48 hours- 7.44 ± 1.67nM 
72 hours- 8.77 ± 1.24 nM 
 
24 hours- 211 ± 120 nM 
48 hours- 138 ± 37.2 nM 
72 hours- 146 ± 35.3 nM 
24 hours - 922 ± 388 nM 
48 hours - 504 ± 261 nM 
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Figure 2.6: Dose-dependent depletion of the Hsp90 dependent client protein Cdk6 by 
17-DMAG.  
Panel A: Representative western blot of Cdk6 depletion as described in Figure 2.3. Panel B: 
Densitometry analysis of Cdk6 depletion from three biological replicates. R
2 
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Figure 2.7: Dose dependent depletion of Hsp90 dependent client protein Cdk6 by 
radicicol. 
Panel A: Representative western blot of Cdk6 depletion as described in Figure 2. 3. Panel B: 
Densitometry analysis of Cdk6 depletion from three biological replicates. R
2 
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Apoptotic effects of 17-DMAG and radicicol were assessed in the same way as described for 
AUY922 (Fig 2.8, Panels A & B respectively). Results indicated that the effects of 17-DMAG 
were largely sub-apoptotic at doses ranging from 1- 133 nM, and the effects of radicicol were 
largely sub-apoptotic at doses ranging from 1-185 nM. Doses above the mentioned concentrations 
for both inhibitors begin to show PARP cleavage indicating that those doses induce cell death.                          
      After characterizing dose-curve responses of all the three Hsp90 inhibitors in Jurkat cells, we 
chose to study their effects on the Jurkat proteome by using 5-7x the IC50 doses for Cdk6 
depletion. Before doing so, I wanted to test the effects of these dosages on cell viability. To 
accomplish this, Jurkat cultures were treated for 24 hours with 75 nM AUY922, 150 nM 17-
DMAG and 300 nM radicicol. Then cell viability was determined by the Trypan blue dye 
exclusion assay. Results showed that more than 80% of the cells were viable after treatment with 
the indicated doses of all three inhibitors (Fig 2.9). Thus we concluded that the 5-7x doses of the 
three inhibitors did not grossly compromise cell viability. 
      After confirming that these doses did not grossly affect cell viability, we treated Jurkat 
cultures for 24 hours with these doses of each inhibitor to study their effects on Jurkat proteome. 
After treatment, cellular proteins were analyzed using the “bottom-up” proteomics approach as 
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Figures 2.8: Apoptotic effects of 17-DMAG and radicicol as assessed by PARP 
cleavage.  
Panel A: Representative western blot for 17-DMAG. Panel B: Representative western blot for 











                               
 
 
Figure 2.9: Effects of 5-7x IC50 doses of AUY922, 17-DMAG and radicicol on Jurkat 
cell viability as assessed by Trypan blue counting. 
Cells were incubated for 24 hours with 5-7x IC50 concentrations of AUY922, radicicol or 17-
DMAG. Live and dead cell counts were performed before and after inhibitor treatments. Results 













      Using the protein identification criteria as described in Methods,  931 proteins were identified 
in cells treated with AUY (FDR of 0.5%), 921 proteins were identified in cells treated with 
DMAG (FDR of 0.5%)  and, 900 proteins were identified in cells treated with radicicol (FDR of 
0.4%). Inhibitor-induced changes in protein expression were analyzed by the spectrum counting 
technique. Upon statistical analysis, 9.7% of the total proteins identified were found to be 
significantly altered by AUY922 (P< 0.05), 8.9% of the total proteins identified were found to be 
altered by 17-DMAG (P<0.05) and 7.6% of the total proteins identified were found to be altered 
by radicicol (P<0.05) (Supplemental excel sheet 1). Among the significant changes in protein 
expression across the 9 experiments (3 inhibitors x 3 biological replicates), 178 proteins showed 
altered expression. Among these 178 proteins, 92 proteins (51.6%) were found to be down-
regulated and 85 proteins (47.6%) were found to be up-regulated. 
       A wide variety of proteins involved in various biological processes were found to be altered 
in amount by all three inhibitors. Among the proteins up-regulated were heat shock protein family 
proteins (large Hsps, small Hsps and chaperonins), Hsp90 co-chaperones, transport proteins, 
RNA processing proteins (especially hnRNPs), tRNA synthetases (glycyl and tyrosyl), a few 
metabolic enzymes (phosphoglycerate dehydrogenase and phosphoserine aminotransferase) and 
proteins involved in ubiquitination and protein turnover. Among the list of down-regulated 
proteins were kinases, helicases, ribosomal proteins, DNA damage/repair proteins, MCM proteins 
and a few metabolic enzymes.  
      Among the significant changes in protein expression across the 9 experiments (3 inhibitors x 
3 biological replicates), 17.4% of the protein expression changes were common to all three 
inhibitors, 23.6% changes were common to at least 2 inhibitors and 44% changes were unique to  
each inhibitor (Fig 2.10).  A summary of protein expression changes common to all three 
inhibitors (Supplemental Table-2.2), at least two inhibitors and (Supplemental Table-2.3) to one 







Figure 2.10: Venn diagram representing protein alterations common and unique to 
















  Proteins expression changes observed with all three inhibitors, or with just two inhibitors, 
showed consistency in expression patterns. Among the list of proteins, proteins down-regulated 
by one inhibitor were down-regulated by the other two inhibitors and proteins up-regulated by 
one inhibitor were up-regulated by the other two inhibitors. Similarly proteins changes common 
to any two inhibitors followed the same trend (with just three exceptions - RPL13A, RAN and 
HNRPDL).  
   From the inhibitor-induced changes identified from LS-MS/MS experiments, seven proteins 
were chosen for confirmation by Western blotting. All of the seven selected proteins were 




















Figure 2.11: Western blotting to confirm inhibitor induced changes in protein 
expression identified from LC-MS/MS experiments. 
Jurkat cultures were treated for 24 hours with various concentrations of indicated inhibitors. 















       In this study, the effects of the new Hsp90 inhibitor AUY922 on Jurkat proteome were 
determined using a label-free LC-MS/MS approach. The effects were also compared to those 
caused by flagship Hsp90 inhibitors 17-DMAG and radicicol. For this comparison, equi-potent 
doses of the each inhibitor were used. Appropriate doses of all three inhibitors were identified 
based on their IC50 doses for depletion of a known Hsp90 client protein Cdk6 (Fig 2.3a, 2.6a & 
2.7a). The IC50 doses for Cdk6 depletion for AUY922, 17-DMAG and radicicol were 12 nM, 27 
nM and 60 nM respectively. Of the three drugs, AUY922 was the most potent.  
      For proteomics assays, 5x to 7x the IC50 concentrations of each inhibitor were used. It was 
also confirmed that these 5-7X doses were largely sub-apoptotic, based on their effects on cell 
viability (Fig 2.9) and PARP cleavage (Fig 2.4, 2.8a &2.8b). Decision to work with these doses 
(75 nM AUY922, 150 nM 17-DMAG and 300 nM radicicol) sets this work apart from  two 
recently published SILAC-based Hsp90 inhibition studies [56, 57] , wherein high micro-molar 
doses of Hsp90 inhibitors (50 µM 17-DMAG and 10 µM GA respectively) were used. These high 
doses of Hsp90 inhibitors cause death of 50% of the cells. Therefore, many of the responses that 
Sharma et al., and Wu et al., observed could be due to the cellular response to apoptosis. 
      All of the three inhibitors generated conserved proteomics fingerprints (Fig 2.10). This 
indicates a conserved mechanism of action, namely Hsp90 inhibition. The most robust, conserved 
responses seen in the proteome were a set of 31 protein expression changes that included  
induction of chaperones Hsp90 alpha, Hsp70, Hsp105, Serpin H1, Spectrin, DnaJ and the T-
complex proteins,  and depletion of Hsp90 clients such as EEF2, Dnmt1, DDX5, CAD protein, 
and the kinases Cdk1, Cdk6. Moreover, these conserved changes showed consistency in 
expression pattern: proteins up-regulated by one inhibitor were found to be up-regulated by the 
other two inhibitors. Similarly, proteins down-regulated by one inhibitor were found to be down-
regulated by the other two inhibitors. This identification of conservation of proteomics 
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fingerprints across three distinct Hsp90 inhibitors strongly validates our mass spectrometry assays 
of Hsp90 inhibition. 
      The proteome-wide changes induced by AUY922, 17-DMAG, and radicicol were consistent 
with the two known hallmarks of Hsp90 inhibition. Traditional Western blotting techniques have 
demonstrated : (i) the induction of a small number of chaperones, especially Hsp70 and (ii) the 
depletion of proteins known to be Hsp90-dependent [41] . In this study, all three inhibitors induce 
a wide variety of chaperones, suggesting the activation of Hsf1 [102]. Additionally, all three 
inhibitors deplete several known Hsp90-client proteins. Demonstrating that all three inhibitors 
display traditional hallmarks of Hsp90 inhibition using mass spectrometry assays supports the 
validity of our mass spectrometry assays. 
      Other observations validate the results from this work. Seven of the protein expression 
changes that were identified by mass spectrometry assays were confirmed using western blotting, 
(Fig 2.11). Not only these inhibitor-induced changes were confirmed, but they were also shown to 
be dose-dependent (Fig 2.11). Additionally, most of the proteins identified as inhibitor-responsive 
in this study have been previously reported to be interact physically or functionally with Hsp90 
[15] . Many of the inhibitor responses that were observed in leukemia cells have also been 
observed in other cancer cell lines treated with Hsp90 inhibitors [56, 57] . All these arguments 
support the validity of the results obtained from mass spectrometry assays. 
    While the above findings indicate the power of mass spectrometry to study Hsp90 inhibitor-
induced changes in protein expression, the technique had certain limitations. Apart from the 
conserved changes in protein expression mentioned above, some changes in protein expression 
were statistically significant in cells treated with two inhibitor treatments, but not in cells treated 
with the third inhibitor (Fig 2.10). For instance, the expression changes for 12 proteins were 
statistically significant in cells treated with AUY922 and 17-DMAG, but not in cells treated with 
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radicicol. Similarly, expression changes for 19 proteins were statistically significant in cells 
treated with AUY922 and radicicol, but not in cells treated with 17-DMAG (Fig 2.10). Moreover, 
there were 11 proteins whose expression changes were statistically significant in cells treated 
with 17-DMAG and radicicol, but not in cells treated with AUY922.  
    We offer for the protein expression changes observed in cells treated with two inhibitors, but 
not identified as statistically significant in cells treated with the third inhibitor: (i) The protein 
expression not identified as significant in only one out of the three assays might be a real change, 
but did not survive the statistical analysis (false negatives, or “type-II errors”), (ii) the protein 
expression changes identified in cells treated with two inhibitors might not be real changes, but 
appeared as significant none the less (false positives, or “type-I errors”) or, (iii) the assays might 
be detecting true, inhibitor-specific changes. Our favorite explanation is that the third drug is also 
altering the expression of these outlier proteins, but they are not being identified as statistically 
significant, due to the weakness of the spectrum counting assays. Thus, we believe that these 
changes fail to survive statistical tests and are thus misinterpreted as false negatives in cells 
treated with the third inhibitor. 
     Similarly, some changes in protein expression appeared unique to cells treated with one of the 
inhibitors, but not for cells treated with the other two inhibitors. Specifically, 35 protein 
expression changes were unique to cells treated with AUY922, 28 protein expression changes 
were unique to cells treated with 17-DMAG and 17 protein expression changes were unique to 
cells treated with radicicol. We offer similar possible explanations for these apparent inhibitor-
specific effects: (i) The inhibitor-specific protein expression changes might not be real (false 
positives) or, (ii) the expression of these proteins might have been significantly altered in cells 
treated with the other two inhibitors, but did not survive the statistical tests (false negatives). 
Again, these assays might be detecting real changes, specific to a single Hsp90 inhibitor. These 
changes could be a combination of type I and type II errors. 
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   Deeper bio-informatics analysis of this data was not performed. It was not well justified to do 
deeper bioinformatics and make big conclusions about the processes altered by these Hsp90 
inhibitors based on the few conserved changes that were identified in this study. 
 
     These data raise several other interesting questions. Are there really only 31 conserved protein 
responses to Hsp90 inhibitors? Does this shortlist of 31 proteins adequately represent the 
proteomics fingerprint of Hsp90 inhibition? Do any of the inhibitors have true drug specific 
effects?  
     Given the nature of the spectrum counting technique, a stronger quantitative proteomics 
technique is required to address the questions raised above. In Chapter IV, these questions will be 







Evaluation of the raw SILAC data and choice of a statistical test for validating 
drug-induced changes in protein expression 
Introduction 
   Before performing a deeper analysis of SILAC data, there was a need to assess the quality of 
the raw data generated from MaxQuant searches to identify potential defects in the data and to 
assess reproducibility across the biological replicates. It was also important to choose appropriate 
statistical tests to validate changes in protein expression caused by the Hsp90 inhibitors. Thus, in 
this chapter, the quality of raw SILAC data from the proteomes of Jurkat cells treated with 75 nM 
AUY922 (AUY922 dataset) were analyzed. Similarly, the quality of the raw SILAC data from the 
proteomes of Jurkat cells treated with 150 nM 17-DMAG (17-DMAG dataset) were also 
analyzed. The quality of raw SILAC data from this study were also compared to the quality of the 
raw SILAC data from two recently published papers describing the proteome-wide effects of two 
other Hsp90 inhibitors. Subsequently, these SILAC data were analyzed using various statistical 
tests. Results from these comparisons will guide the choice of statistical tests that will be used to 
analyze AUY922 and 17-DMAG SILAC data. 
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 Materials and Methods 
Materials  
96-well TARGA C18 macrospin plates were purchased from Nest group (Catalog number SNS 
SS18R) 
General cell culture and inhibitor treatments 
   To prepare SILAC “light” fractions, Jurkat cells were cultured in SILAC RPMI media 
containing 10% dialyzed FBS and supplemented with light isotopic lysine (C6H14N2O2) and 
arginine (C6H14N4O2) amino acids. For preparing “heavy” SILAC fractions, Jurkat cells were 
cultured in SILAC RPMI media supplemented with heavy isotopic lysine (13C6H14 15N2O2) and 
arginine (13C6H14 15N4O2) amino acids. Conditions for culturing cells were otherwise the same as 
described in Chapter II.   To assess the impacts of Hsp90 inhibitors on the Jurkat proteome, cells 
growing in SILAC light media were treated with DMSO, while cells growing in SILAC heavy 
media were treated either with 75 nM AUY922 or 150 nM 17-DMAG. After 24 hour incubation 
cells were harvested and lysed as described in Chapter II. Protein concentrations in the lysates 
were estimated by Bradford assays. 
Sample preparation for mass spectrometry 
    Fifty micrograms of untreated (light) Jurkat lysate were mixed with fifty micrograms of 
inhibitors-treated (heavy) lysate. Samples were then precipitated with TCA/acetone using the 
protocol described in Chapter II. Protein pellets were resolubilized in 2x SDS sample buffer, and 
proteins were reduced by 10 mM DTT and alkylated with 50 mM IAA. Proteins were then 
fractionated on precast mini-gradient gels (4-20% Bio-Rad). Each lane was excised with a razor 
blade to produce ten fractions. Gel bands in each fraction were sliced into small pieces. Slices 
were then washed with 25 mM ammonium bicarbonate / 50% acetonitrile and dehydrated with 
55 
 
ACN. Gel slices were briefly air dried, then rehydrated with 25 mM ammonium bicarbonate 
containing 8 µg/ml trypsin. Digestion was performed overnight at 37° C. Peptides in each fraction 
were then extracted with 60 µl of 0.5% TFA. Salts in the peptide samples were cleaned using 
Nest group’s TARGA C18 96 well plates.  Peptides were vacuum dried and analyzed by LC-
MS/MS. 
LC-MS/MS analysis  
    LC-MS/MS analysis was performed on a Thermo Fisher Scientific hybrid LTQ-Orbitrap XL 
mass spectrometer. A New Objective PV-550 nanoelectrospray ion source was used for 
electrospray ionization. An Eksigent 1-D UPLC system was used to separate the peptides. 
Peptides were first trapped on a trapping column in a vented column configuration (5 cm of 3 μm 
Magic C18 AQ). Trapped peptides were then separated on a 75 μm ID 40-cm fused silica column 
(3-μm Magic C18 AQ), terminated with an integral fused silica emitter. Peptides were eluted by 
using a 0-37% ACN/0.1% formic acid gradient over 220 min at a flow rate of 250 nL/min.  
    Eluted peptides were analyzed using a data dependent scanning mode, automatically selecting 
specific ions for MS/MS analysis. The full scan MS spectra for ions 360-1400 m/z were acquired 
in the Orbitrap sector, providing a nominal resolution of 60,000 FWHM. Lock-mass was enabled 
for internal calibration on the polysiloxane [C12H3706 ]
+1 
ion (m/z 445.1200). For MS/MS, the six 
most abundant peptides were selected for further fragmentation in the ion trap by the CID 
(collision induced dissociation). For MS/MS analysis, only ions with intensities greater than 
8,000 were chosen. To optimize the instrument duty cycle, only mono-isotopic precursors were 
selected for MS/MS. Parent ions with unassigned charges were not chosen for further MS/MS 
analysis (because their m/z values cannot be determined). Ions previously identified as 
contaminants, and ions already selected for MS/MS analysis (using dynamic exclusion at 150% 



















     Raw LC-MS/MS data were processed using MaxQuant (Version 1.3.0.5). The Andromeda 
search engine was used for database searches. Database searches were done against 
Uniprot_human database (Released on 2013_03) containing 87,656 sequences. Additionally 
database searches included known contaminants as well as reverse protein sequences. Searches 
also included hypothetical peptides with variable modifications oxidation (M), acetyl (protein N-
term), carbamidomethyl (C), Gln to pyro-Glu and Glu to pyro-Glu. Trypsin was specified as the 
digestion enzyme allowing up to two missed cleavages. Minimum peptide length for 
identification was set to 7 amino acids. Search thresholds utilized a peptide and protein false 
discovery rate (FDR) of 0.01. Fragment ion mass tolerance was set to 0.5 Da. MaxQuant 
determines the parent ion mass tolerance on the basis of mass accuracy achieved and hence was 
not specified. 
Data normalization 
    Data in each biological replicate were normalized using a global normalization approach. 
Treated (Heavy, H) and untreated samples (Light, L) are hereafter referred to as separate 
channels. Normalization for each channel was done separately. The normalization factor for each 
protein in each channel of each biological replicate was calculated by dividing the raw intensity 
of that protein in that channel of that bio-rep by average raw intensity of that protein across all of 
the bio-reps.  
 (Normalization factor for a protein (X) in L or H channel = Raw intensity of X in L or H 
channel in a bio-rep / average intensity of X in L or H channels in all 5 bio-reps). 
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    Using the normalization factors for all in each L/H channel of a bioreps, an average 
normalization factor for whole L/H channel in that bio-rep was obtained by averaging the 
normalization factors  of all the proteins in that bio-rep.  
  (Normalization factor for each bio-rep = Median of normalization factors of all proteins in 
that bio-rep). 
   This generated an average normalized factor for each H/L biorep. Subsequently the intensities 
of each protein in that bio-rep were normalized by dividing their raw intensities by the channel-
specific normalization factor. 
Statistical analysis 
      The distribution of the heavy and light populations was identified using the Shapiro-Wilk test 
using the code in the R-program. Variances across the light and heavy populations were 
determined using the F-distribution function in Microsoft Excel. Student’s T-tests were 
performed using functions in Microsoft Excel. One sample T-tests were performed using software 
package Perseus. Benjamini-Hochberg (B-H) FDR correction [103] of the one sample T-test p-
values were performed using the code in R . Storey FDR [104] correction  of the one sample T-









Evaluation of raw SILAC data from Jurkat cells treated with Hsp90 inhibitor 
AUY922 
Reproducibility across five biological replicates 
   In order to assess the reproducibility of our SILAC data, we compared data from all of our five 
biological replicates of Jurkat cells treated with AUY922 (AUY922 is an Hsp90 inhibitor). For 
each of the proteins quantified, ratios of protein expression in treated cells (H) vs. control cells 
(L) (Heavy/Light ratios) from one biological replicate were log2 transformed, and plotted against 
the protein expression changes observed for each of the other 4 biological replicates (Fig 3.2). 
Each of the individual scatterplots can be divided into four quadrants through its log2 equals zero 
values (no change in expression) on both the X and Y axes. Proteins (dots) represented in the 
lower left-hand quadrant indicate proteins down-regulated in both the biological replicates. 
Proteins (dots) represented in the upper right hand quadrant indicate proteins up-regulated in both 
the biological replicates. Proteins (dots) represented in the other two quadrants indicate proteins 
up-regulated in one biological replicate, but down-regulated in the other biological replicate. The 
majority of the proteins were distributed in the lower left quadrant and the upper right quadrant in 
all the scatterplots, and there were very few proteins in the lower right hand quadrant and in the 
upper left hand quadrant. This indicated that down-regulation and up-regulation were consistent 




Figure 3.2: Reproducibility across biological replicates in AUY922. 
Each dot represents protein expression changes (Log2 ratio H/L) from one biological replicate 
analyzed against protein expression changes from each of the other 4 biological replicates. The 
X-axis and the Y-axis represent fold changes in protein expression. AUY denotes cells treated 






regulated in one bio-rep but down-regulated in the other bio-reps. The degree of agreement 
between biological replicates is indicated by coefficient of variance (R
2
, calculated using a linear 
fit),
 
which is presented on the top left corner of each scatterplot. The R
2
 values for the 
comparisons across different biological replicates ranged from 0.771 to 0.844. The strength of the  
R
2 
values across different comparisons indicated good experimental reproducibility. Based on the 
distributions of proteins on the scatterplots, and the generally strong R
2
 values, we concluded that 
our assays were highly reproducible across the five biological replicates. 
      In order to further assess the quality of our data, we similarly analyzed the raw data (Fig 3.3) 
from Sharma et al. [56] characterizing the proteomes of HeLa cells treated with 50 µM 
geldanamycin. Their R
2 
values ranged from 0.54 to 0.701. Additionally, their data showed more 
outliers (points that deviate from best fit line) than those observed in our data (c.f. Fig 3.2 vs. Fig 
3.3). Based on the comparison of their R
2
 values to our R
2
 values, our reproducibility across our 
five biological replicates was as good/better compared to data from Sharma et al. However, it 
should be noted that the number of proteins they assayed (7,056 proteins) was much higher 
compared to our assays (3,146 proteins). This would make their outliers more visible, when 
visually compared to our data (c.f. Fig 3.2 vs. Fig 3.3).  
Data normalization 
    For SILAC analysis, heavy-labeled and light-labeled samples should be mixed ideally in an 
equal mass to mass ratio. Here, it will referred to as channel-level normalization. Similarly, 
artifactual differences in the intensities of heavy and light ions caused by errors in sample-level 
mixing will be referred to as imperfect channel-level normalization.  
There are two possible sources for imperfect channel-level normalization. The first source could 
be imperfect protein quantification of the individual light and heavy lysates (e.g., imperfect 
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Figure 3.3: Reproducibility across biological replicates in data from Sharma et al. [56]. 
Reproducibility of data from Sharma et al. [56], was assessed by comparing protein expression 




Bradford assays). A second source could be imperfect pipetting of the light and heavy lysates 
during mixing. 
A different source of artifactual variability in SILAC data is potential changes in ionization 
efficiency as the spray tip ages, and/or aging of the instrument’s electron multipliers. This is 
relevant, because our SILAC datasets were run 24 hrs. / day, 7 days / week, for 60 days. Thus,  
either or both of these sources can distort the comparison of raw peptide ion intensities across 
different biological replicates.  
    Therefore it is important to assess potential normalization defects prior to statistical analysis of 
the data. To do this, we log2 transformed each “protein raw intensity” (values calculated by 
MaxQuant, representing individual protein abundances) in each channel (H or L) across the five 
biological replicates, and plotted the distributions of these values as histograms. We also 
transformed the raw H/L ratios, and similarly plotted their distributions. To compare the 
reproducibility among the five biological replicates, we overlaid histograms of all 5 bioreps (Fig 
3.4). 
    For the raw intensities, this overlay did not reveal major issues. However, a similar analysis of 
ratios showed that there were normalization problems between biological replicates. H/L ratios 
from biological replicates 2, 3 and 4 were very similar (Fig 3.4). In contrast, biological replicates 
1 and 5 showed lower H/L ratios (Fig 3.4). Based on these observations, we concluded that there 
were channel-level normalization defects across the five biological replicates, and we concluded 
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Figure 3.4: Assessment of the quality of raw intensities and raw ratios in AUY922 data. 
The frequencies of raw light and heavy protein intensities (Panels A & B, respectively), and raw 
H/L ratios (Panel C) from the 5 bio-reps were plotted as distributions (histograms). The X-axis 
represents arbitrary binning of proteins based on intensity. The Y-axis represents the respective 











    We extended our examination of the quality of the raw data by plotting each protein’s raw H/L 
ratio versus its raw protein intensity (Fig 3.5). In biological replicates 2, 3 and 4, the majority of 
the proteins on the graph were nearly centered on log2 0 on the X-axis (Fig 3.5, panels B, C, D), 
indicating good normalization of the treated and control samples. In contrast, in biological 
replicates 1 and 5 the majority of the proteins showed a larger offset from the log2 0 on the X-axis 
(Fig 3.5, panels A & F). These observations reinforced our conclusion that the biological 
replicates 2, 3 and 4 were well normalized at the channel level, but that the biological replicates 1 
and 5 were imperfectly normalized. 
    Because there were normalization defects across the five biological replicates, we performed a 
global normalization of the protein intensities in the control and treated samples. To accomplish 
this, we normalized each protein’s raw intensity using the normalization approach described in 
the Materials and Methods section for this chapter. After normalization, the reproducibility across 
the five biological replicates was enhanced, as evident by a more uniform distribution of H/L 
ratios among bioreps (Fig 3.6C). Thus, our normalization strategy successfully minimized 







       
Biological replicate 1             Biological replicate 2           Biological replicate 3    
                                         
                             Biological replicate 4                   Biological replicate 5           
Figure 3.5: AUY922 raw data before normalization –Ratio versus intensity plots 
Protein expression changes (log2 ratio H/L) from each biological replicate were plotted against 
the protein abundance to assess normalization defects. The X-axis represents the protein 
expression and is expressed in log2 scale. The Y-axis represents the protein abundance. Each spot 
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Figure 3.6: Global normalization minimized reproducibility issues across the five 
biological replicates in AUY922. 
Normalized light and heavy intensities (Panels A & B), or normalized ratios (Panel C), from the 










We extended our analysis by visualizing the effects of normalization using ratio versus intensity 
plots. The log-transformed normalized H/L ratios vs. intensities from all the five biological 
replicates were reproducibly oriented with regards on the log2 of the X-axis (Fig 3.7). This 
visualization confirmed that our normalization strategy minimized variability across the five 
biological replicates (c.f. Fig 3.7 vs. Fig 3.5). 
 
Does normalization affect the data quality? 
     To assess if our normalization strategy compromised the H/L ratios, we compared 
distributions of H/L ratios before and after normalization. To do this, we averaged the raw H/L 
ratios and normalized H/L ratios from 5 biological replicates and plotted these distributions as a 
histogram. Mean histogram of H/L population distribution before normalization and after 
normalization were nearly identical (c.f. 3.8A vs. 3.8B). This indicated that the normalization did 
not grossly distort the protein expression ratios. In contrast, comparison of the individual raw vs. 
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Figure 3.7: AUY922 raw data after normalization –Ratio versus intensity plots. 
Protein expression changes (log2 ratio H/L) from each biological replicate were plotted as 
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Figure 3.8: Histograms of average protein expression of all five biological replicates in 
AUY922 before and after normalization. 
Log 2 of the ratios of H/L intensities from all the five biological replicates were averaged and 
plotted as histograms before (Panel A) and after normalization (Panel B). The X-axis represents 
binning of proteins based on abundance. The Y-axis represents the number of proteins in each 
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Figure 3.9: Histograms of protein expression from individual biological replicates in 
AUY922 before and after normalization. 
Protein intensities from control and treated samples of AUY922 dataset were normalized using 
global normalization approach as described in the text. Protein expression across the five 
biological replicates were plotted before (Panel A) and after normalization (Panel B) as described 
in Figure 3.8. 




 Results from Western blotting assays in our spectrum counting work consistently showed that 
actin expression was unaltered even after treating cells with a high dose of Hsp90 inhibitors (Fig 
2.11, Chapter II). Therefore, we assessed the expression (H/L ratios) of actin and other house-
keeping genes before and after normalization (Table 3.1). Results showed that average H/L ratios 
for house-keeping genes before and after normalization were almost identical indicating that our 
normalization did not distort the data (consistent with Fig 3.8). Moreover, the average 
normalization factor values across the biological replicates were all nearly the same after 
normalization indicating that our normalization minimized variability across the biological 
replicates (consistent with Fig 3.6c). 
 
Comparison of our data with two recently published SILAC based studies on Hsp90 
inhibition. 
      Two recent publications utilized SILAC approaches to report the effects of Hsp90 inhibitors 
on cellular proteomes. The publication from Sharma et al. [56]  reported proteome-wide changes 
in HeLa cells treated with 50 µM 17-DMAG [56]. The publication from Wu et al [57] , reported 
the effects of 5 µM to 10 µM geldanamycin on the proteomes of MDAMB231, K562, Colon205 
and Cal27 cell lines [57]. 
    We compared our data to the raw SILAC data from these two studies. To accomplish this, we 
plotted histograms representing the raw protein expression ratios from the 5 biological replicates 
of HeLa cells treated with 17-DMAG [56]  and from the 3 biological replicates of MDAMB231 
and Colon205 cells treated with geldanamycin [57]. The data from Sharma et al. showed protein 








Table 3.1: H/L ratios of house-keeping proteins across five biological replicates in 
AUY922 before and after normalization 
The H/L ratios of house-keeping genes from all five bioreps were calculated and tabulated before 
and after global normalization. Additionally, the average ratios before and after normalization, 
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normalization defects apparent across their biological replicates. Their normalization defects were 
similar to those observed in our data (c.f. Fig 3.10 vs. Fig 3.9). Based on these observations, we 
concluded that their normalization defects were comparable to those that we experienced. We 
also concluded that the majority of their proteome was down-regulated upon Hsp90 inhibition, 
similar to the down-regulation apparent in our data.  
    In contrast, raw data of Wu et al. representing the proteomes of MDAMB231 cells treated with 
5 µM geldanamycin appeared perfectly reproducible across the three biological replicates (Fig 
3.10, Panel B). Their raw H/L ratios were greater than 0, but not less than 0 implying up-
regulation of majority of the proteome (Fig 3.10, Panel B).   Despite raw ratios from cells treated 
with MDAMB231 implying up-regulation, after variance stabilization normalization (VSN), Wu 
et al. concluded that there were more down-regulated proteins (247 proteins) than the up-
regulated proteins (232 proteins).  By analyzing MDAMB231 dataset from Wu et al. and noting a 
discrepancy from their conclusion that more proteins are down-regulated versus their actual raw 
data indicating up-regulation, we felt that the quality of their raw data was weaker than our raw 
data. Both our raw data and statistical analysis of the data, agreed with each other, by indicating 
down-regulation of the proteome. 
    However, their raw data from their Colon205 cells treated with 10 µM geldanamycin were very 
different across the biological replicates (Fig 3.10, Panel C). Moreover, in their Colon 205 raw 
data, one biorep implied up-regulation whereas the other two implied down-regulation (Fig 3.10, 
Panel C), whereas our raw data had consistent down-regulation across all five bioreps (Fig 3.9, 
Panel A). I note that their sample level normalization was done by mixing treated and untreated 
cells directly, rather than lysates. Moreover, at 10 µM dose of geldanamycin 50% of their cells 
were dead (Supplementary Figure S1 from Wu et al. [57]). This raises questions about their 
normalization at the cell level, rather than the protein level. Thus, based on these comparisons we 
concluded that our raw data was better than the data from Wu et al. 
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Figure 3.10: Assessment of the quality of raw data from Sharma et al. and Wu et al. 
H/L protein expression ratios from references [56] (Panel 10A) & [57]  (Panel 10B & 10C) were 





Analysis of our raw data from cells treated with 150 nM 17-DMAG 
 
   In preceding sections, we discussed the analysis of raw data from cells treated with AUY922, 
and compared that data to data from other studies. Here, we similarly analyze our SILAC dataset 
from cells treated with a second Hsp90 inhibitor namely, 17-DMAG (Fig 3.11, 3.12 and 3.13). 
Results showed a good degree of reproducibility across the five biological replicates (Fig  3.11), 
evident by R
2
 values ranging from 0.791 – 0.835 and by the clustering of the data in upper right 
hand quadrant or lower left hand quadrant of scatterplots of protein intensities among 
experiments (Fig 3.11).  
      Additionally, our data from cells treated with 17-DMAG reinforced our conclusions that a 
large portion of the proteome was down-regulated in cells treated with Hsp90 inhibitors (Fig 3. 
16). Minor normalization problems (Fig 3.12 & 3.13) prompted us to normalize the data using the 
same approach as described for proteomes isolated from cells treated with AUY922. As we 
described for AUY922 dataset, this normalization minimized the variation and enhanced 
reproducibility across the five biological replicates (Fig 3.14, 3.15 & 3.16), but without distorting 








Figure 3.11: Reproducibility across biological replicates in cells treated with 17-
DMAG. 
Protein expression changes (Log2 ratio H/L) were plotted across the five biological replicates as 













Figure 3.12: Assessment of the raw ratios in cells treated with 17-DMAG. 
The frequencies of raw ratios from the 5 biological replicates were plotted as histograms as 
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Figures 3.13: 17-DMAG raw data before normalization. 
Protein expression changes (log2 ratio H/L) from each biological replicate were plotted against 




















Figure 3.14: Global normalization minimized reproducibility issues across the five 
biological replicates in 17-DMAG. 
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Figure 3.15: 17-DMAG data after normalization –Ratio versus intensity plots. 
Protein expression changes (log2 ratio H/L) from each biological replicate were plotted as 
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Figure 3.16: Histograms of protein expression from individual biological replicates in 
17-DMAG before and after normalization. 
Protein intensities from control and treated samples of 17-DMAG dataset were normalized using 
global normalization approach as described in the text. Protein expression across the five 
biological replicates were plotted before (Panel A) and after normalization (Panel B) as described 
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Figure 3.17: Histograms of average protein expression of all five biological replicates 
in 17-DMAG before and after normalization. 
Ratios of H/L intensities from all the five biological replicates were averaged and plotted as 
histograms before (Panel A) and after  normalization (Panel B). The X-axis represents binning of 

















Assessment of the population distribution of protein intensities in our AUY922 
dataset 
    To decide which statistical tests were most appropriate for our data, we first determined 
whether our data followed a normal distribution. To do this, we pooled all protein intensities from 
all 5 bio-reps, and applied the Shapiro-Wilk test to determine if the data followed normal 
distribution. Results showed that the p-values for our dataset were greater than the chosen alpha 
level (Light Stat: 0.89, Light p-value: 0.19 Heavy Stat: 0.85, Heavy p-value: 0.19). This indicated 
that our data followed a normal distribution. This normal distribution was also evident in visual 
representation of the data populations (Fig 3.18). Thus, we concluded that Student’s T-test might 
be an appropriate choice to validate significant changes in protein expression among treated 
versus un-treated cells.  
  To perform a Student’s T-test, we had to decide whether to use statements of equal variance vs. 
un-equal variance between protein intensities from 5 treated samples and 5 untreated samples. 
Thus, we analyzed treated and control populations using the F-distribution function in Microsoft 
Excel. Results showed that the F-ratio was higher than the critical F-value (FINV) at the 90% 
confidence interval (Table 3.2).Thus, we concluded with 90% confidence that the two 
populations did not have equal variances. Thus, we concluded that T-test, two-sided (since we do 
not know the direction of the change), with unequal variance would be appropriate test for 
identifying significant drug-induced changes in protein expression. 
  After identifying Student’s T-test as an appropriate test, this test was used to analyze AUY 922 
data (two sided with statements of unequal variance). Very few protein changes out of the total 
proteins altered were identified as significant using this test (13%). Applying the B-H FDR  





                    




Figure 3.18: Assessment of the distribution of light and heavy intensities in AUY922. 
 
The populations of light intensities and heavy intensities were plotted as histograms to assess the 
distribution (Panel A & B respectively). The X-axis represents binning of proteins based on their 






Table 3.2: F-distribution test to determine if treated versus control populations have   



















=(Confidence, Total count heavy-1,Total count light-1) 
0.979536857 
 
Variance for the light and the heavy populations in AUY922 were calculated using VARP 
(variance of the population) function. Ratio was calculated by dividing VARP Heavy by VARP 











correction the number of significant proteins reduced this to 3%. Adding a third filter to require 
1.5 fold change further reduced the number of significant changes down to 2%. 
      Similarly we analyzed raw data from Wu et al. representing MDAMB231 cells treated with 5 
µM geldanamycin [57]. After Student’s T-test and B-H FDR correction, very few proteins from 
the total proteins were identified as significant. Furthermore, with B-H FDR correction and the 
1.5 fold threshold, none of the proteins were identified as significantly altered in their data (Table 
3.3). 
   In contrast, my analysis of each protein’s average expression ratio in treated versus un-treated 
cells suggested that the majority of the cellular proteome was down-regulated upon Hsp90 
inhibition (Fig  3.7, 3.8 & 3.9). In 5/5 experiments, the majority of the protein ratios 
(treated/untreated) were represented on the left side of the log2 scale, as opposed to being 
distributed uniformly on the left and right sides of the log2 scale. (Fig 3.8A & 3.8B).This 
indicated that much of the proteome was being reproducibly down-regulated upon Hsp90 
inhibition. This contrasts with the results from Student’s T test above, where only 2% of the 
proteome changes were identified as significant. This suggested that Student’s T-test with B-H 
FDR correction and 1.5 fold change criteria probably understate the significant changes in protein 
expression caused by drug treatment. Thus, we concluded that Student’s T-test is not an 
appropriate test for reporting significant drug-induced changes in protein expression. 
     In order to assess other statistical methods that might be used to validate changes in protein 
expression, we assessed our data, data from Sharma et al. [56], and the data from Wu et al. [57]  
using the one sample T-test used by Sharma et al. [56]. However, Sharma et al. did not describe 
their statistical analysis in their publication [56] . Therefore, we de-constructed their statistical 
analysis. For this, we analyzed their normalized H/L ratios from all the five biological replicates 
using the “One sample T-test” function embedded in their software package Perseus. Their  
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Table 3.3: Comparison of the effects of statistical tests on 3 Hsp90 inhibited proteomes 
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       Datasets- % of proteins responding to Hsp90 inhibition 
Our AUY922 dataset 
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treated/untreated ratios were presumably normalized by MaxQuant during peptide peak detection, 
capture and collection into protein intensities. Using this test, we identified 2,861 changes in 
protein expression in their dataset with T-test p values < 0.05 (out of the 7,028 total proteins 
assayed). However, their final list of up-regulated and down-regulated proteins contained only 
2,107 proteins whose expression was altered. In order to reconcile these two numbers, we applied 
the B-H FDR correction embedded in their software package Perseus (B-H = 0.05 FDR) to their 
T-test p values. This correction invalidated proteins with a t-test p value ≤ 0.015. This allowed us 
to exactly duplicate their list of significantly altered proteins and their p values (Fig 3.19). 
    Using this approach, we analyzed normalized data from Wu et al. (MDAMB231 cells treated 
with 5 µM geldanamycin using the one sample T-test used by Sharma et al. Using this test, 43% 
of the total proteins altered were identified as significant. The number of significantly altered 
proteins reduced to a 24% by applying a B-H FDR correction.  
   Applying 1.5 fold threshold along with B-H FDR correction further reduced the number of 
significant proteins to 14% (Table 3.4). Thus, we concluded that the number of proteins identified 
as significantly altered in data from Wu et al. were reduced to similar extent relative to data from 
Sharma et al. 
   Subsequently we analyzed our normalized AUY922 data using the one sample t-test. We 
identified 57% of the total proteins as being significantly altered. The B-H FDR corrections 
further reduced the number of significantly altered proteins to 51%. Applying 1.5 fold threshold 
further reduced the number of significantly altered to 12%. Thus, we concluded that the number 
of significantly altered proteins in our AUY922 dataset was reduced to by applying both B-H 
FDR correction and 1.5 fold threshold and that this reduction was similar to the reduction 
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Figure 3.19: Comparison of deconstructed data from Sharma et al. to their actual data. 
Statistical analysis from Sharma et al. was de-constructed using one sample T test embedded in 
their software package Perseus, and results were compared by plotting the –log (p values) from 
published data of Sharma et al. versus my de-constructed –log (p values). Panel A: Comparison 
of p values for significantly up-regulated proteins and Panel B:  Comparison of p values for 









   The B-H FDR test is a test for multiple corrections. It is designed to validate only a few 
significant differences in a large dataset. However, when there are many significant differences in 
a large dataset, the Storey FDR test is a more appropriate test. Similar to B-H FDR test, Storey 
FDR test is a false discovery correction test that validates larger p-values than the B-H FDR test. 
This helps to validate more positives in datasets that have large numbers of differences. 
Our AUY922 dataset suggested that the majority of the proteome was down- regulated by Hsp90 
inhibition. Similarly, we had many proteins with significant one sample T test p values. Thus, the 
Storey FDR test was more appropriate than the BH- FDR test for our data. Therefore, we applied 
the Storey FDR to the p values from our T-test and identified 10% more proteins as significantly 
altered, than those we identified using B-H FDR correction. After applying 1.5 fold threshold, the 
number of proteins identified as significantly altered reduced to 14%, thus suggesting that 1.5 
fold threshold is very rigorous and eliminates more than half of the proteins. Thus, we identify a 
short list of protein expression changes with high confidence. 
    We similarly re-analyzed normalized data from Sharma et al and Wu et al. using a Storey FDR 
correction and 1.5-fold threshold (Results shown in Table 3.1). The number of proteins identified 
as having significant alterations in protein expression using B-H FDR test and Storey FDR test 
were the same for the data from Sharma et al. Similarly, in data from Wu et al, Storey and B-H 
FDR tests identified the same number of proteins with significant alterations in protein 
expression. Applying an additional 1.5 fold threshold to both the datasets (Sharma and Wu) 
reduced the total number of proteins with significant changes in protein expression to about 14%. 
  Thus, we concluded that one sample T-test with Storey FDR correction and 1.5 fold change 
threshold criterion is an appropriate approach to report highly confident changes in protein 






     In summary, analyzing our raw SILAC data representing the proteomes of Jurkat cells treated 
with AUY922, we noted minor normalization problems across the 5 biological replicates (Fig 3.4 
& 3.5). By comparing the quality of our raw data to the raw SILAC data of other cell lines treated 
with Hsp90 inhibitors we concluded that  our raw data were as good as data from Matthias 
Mann’s lab [56] , (c.f. Fig 3.2 vs. Fig 3.3), and perhaps superior to the data from David Kuster’s 
lab [57], (c.f. Fig 3.2 vs. Fig  3.10B & 3.10C).  
  To address our minor normalization defects, we developed a global normalization strategy. Our 
strategy minimizes variation across the biological replicates (Fig 3.6 & 3.7), but does not distort 
the data (Fig 3.8 & 3.9).  
   We demonstrate that while the Student’s T-test might be appropriate for validating our data, we 
show that the one sample T test used by Manns’group is more appropriate test for identifying 
significant changes in protein expression (c.f. Table 3.3 vs. Fig  3.8 & 3.9). 
  Therefore our final choice was to include a 1.5 fold change threshold criterion but with the 
Storey FDR correction of one sample T-test to generate a short-list of proteins in which we have 
high confidence, rather than reporting a larger list of changes which we are not confident. We will 
go on to use these criteria to analyze 5 other SILAC datasets collected in subsequent experiments 






The proteomics fingerprints of AUY922 and 17-DMAG are largely similar in Jurkat 




     In Chapter II, we quantified the changes in protein expression induced by anti-cancer drug 
candidate, AUY922 in Jurkat leukemia cells using the spectrum counting approach. We compared 
AUY922-induced changes to the expression changes induced by classical Hsp90 inhibitors 17-
DMAG and radicicol. Using this approach, we identified around 180 proteins showing significant 
changes in expression. Although we identified 31 protein expression changes that were common 
to all three inhibitors, we also identified changes that were not universal. Thus, we were faced 
with questions about which of these changes were real.  
   To address these questions, and also to identify more protein expression changes induced by 
Hsp90 inhibitors, a better quantitative proteomics approach was needed. In this chapter, the stable 
isotope labeling with amino acids in cell culture (SILAC) approach was used to compare the 
proteomic fingerprints of AUY922 and 17-DMAG. Results from this study were anticipated to 
validate findings from our spectrum assays. It was also anticipated that SILAC would allow 
identifying more inhibitor-induced protein expression changes so that a stronger and deeper 
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proteomics fingerprint of Hsp90 inhibition could be established. The proteins thus identified in 
this study would serve as candidate biomarkers for Hsp90 N-terminal inhibitors. Identification of 
the proteomics fingerprint of Hsp90 C-terminal inhibitors is one of the long term goals of our 
laboratory. Therefore the proteomics fingerprint of Hsp90 N-terminal inhibitors identified in this 
study could be compared to the fingerprint of Hsp90 C-terminal inhibitors. This would give 
insights into the mechanism of action of both classes of inhibitors and would reveal if they have 
similar or different mechanisms of action. 
Materials and Methods 
    All the materials and methods and statistical testing used in this study were the same as 
described in Chapter III. A summary of the experimental design was described in Chapter III. In 
order to identify the significant alterations in protein expression, normalized H/L ratios were 
validated by one sample T-test, with multiple tests correction using the Storey FDR test. The final 
list of proteins with significant alterations in expression consisted of proteins with greater than 
1.5 fold changes in expression and Storey FDR values less than 0.05.  
Drug treatments and LC-MS/MS analysis 
    Jurkat cultures adapted to SILAC heavy media were treated for 24 hours with 75nM or 150nM 
of AUY922 or 17-DMAG respectively. These doses represent 5-7X IC50 doses for Cdk6 
depletion (See Fig 2.3 & 2.6 from Chapter II). As controls, Jurkat cultures adapted to SILAC light 
media were treated with DMSO. All the experiments were performed in five biological replicates. 
Protein in the cell lysates from drug-treated and control samples were quantified, mixed in a 1:1 
ratio (50 ug of treated lysate + 50 ug of untreated lysate), precipitated with TCA/acetone and 
fractionated by SDS-PAGE. Following fractionation, samples were trypsinolyzed and processed 
as described in the Materials and Methods section of Chapter III. Resulting trypsinolytic peptides 
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were analyzed by LC-MS/MS analysis using a Thermo LTQ-Orbitrap XL mass spectrometer. 
Protein identification and quantification was performed using MaxQuant (v 1.3.0.5). 
GO analysis 
   Proteins with significant changes in expression were categorized for biological process, 
molecular function and cellular component using the DAVID bioinformatics program [105]. To 
gain insights into the functional categories represented, functionally related GO terms were 
grouped using web server REVIGO [106] with the following default settings : Allowed 
similarity- medium (0.7), number associated to GO categories are – p-values, database with GO 
term sizes –whole Uniprot, semantic similarity measure to use -SimRel. For REVIGO analysis 














      In this study, impacts that two distinct Hsp90 inhibitors, namely AUY922 and 17-DMAG, 
have on the proteome of Jurkat leukemia cells were assessed using a SILAC approach. To 
identify how reproducible the biological replicates in the AUY922 dataset were, we compared the 
total number of proteins identified in all the 5 biological replicates. Results indicated that 
majority of the proteins identified (2,400) were observed in all the 5 biological replicates (Fig 
4.1). Thus, we concluded that there was a high degree of reproducibility across the 5 biological 
replicates in AUY922 dataset. Similarly, we compared the reproducibility across the 5 biological 
replicates in 17-DMAG dataset using the same approach as described for AUY922. Results 
indicated that similar to AUY922, 17-DMAG dataset also displayed a high degree of 
reproducibility with majority of the proteins identified (2193) being observed across the 5 
biological replicates (Fig 4.1). 
  To identify how similar the AUY922 and 17-DMAG datasets were, we compared the total 
number of proteins identified across the 5 biological replicates in both the datasets. Results 
showed that the size of both the datasets were similar as indicated by the total number of proteins 
identified in all the 5 biological replicates (Fig 4.1). Thus, we concluded that both the datasets 
were highly similar to each other in terms of the number of proteins identified. 
    Prior to determining how conserved the protein expression changes between AUY 922 or 17-
DMAG treated Jurkat proteomes were, changes in protein expression  induced by the drugs were 
validated using one sample T-test. Results showed that the one sample T-test yielded nearly a 
similar number of protein expression changes with p < 0.05 in both AUY922 and 17-DMAG 
datasets and suggested that 50% of the proteome was being altered by both drugs (Fig 4.2A). 
Thus, we concluded that the one sample T-test had similar effects on both AUY922 and 17-






Figure 4.1: Total number of proteins detected across biological replicates in the 
proteomes of Jurkat cultures treated with AUY922 and DMAG. 
The total number of proteins detected across the five biological replicates in the proteomes of 
Jurkat cultures treated with AUY922 and 17-DMAG are represented. N represents the number of 
biological replicates. The N = 5 circle represents the number of proteins identified in 5/5 
experiments. The N = 4 crescent represents the difference between the number of proteins 
identified in 5/5 experiments vs. the number of proteins identified in 4/5 experiments (and so on 






similar. This was highly consistent with our raw data that suggested that the majority of the 
proteome was being down-regulated upon Hsp90 inhibition (Fig  3.7 and 3.18, chapter III).  
   To minimize reporting false positive changes in protein expression and to avoid missing any 
true changes, we then performed multiple test correction of the T-test p-values from both 
AUY922 and 17-DMAG datasets using the Storey FDR test setting the FDR < 0.05. This slightly 
reduced the total number of protein expression changes identified as significantly altered in both 
AUY922 and 17-DMAG datasets (c.f. Fig 4.2A vs. Fig 4.2B). After this Storey FDR correction, 
59% of the total identified proteins showed significant changes in expression that were common 
between both drugs (Fig 4.2B). The large degree of overlap in the number of significantly altered 
proteins among the two drugs reinforced our conclusion that their effects were largely similar.  
    In order to report only the protein expression changes which we had high confidence in, we 
applied a 1.5-fold change criterion in conjunction with the Storey FDR correction. Among the 
total proteins with expression changes ≥ 1.5-fold in both the drugs, 49% of them were the same 
between both drugs (Fig 4.2C). We then compiled the total number of proteins that pass both 
criteria (Storey corrected values < 0.05 and fold change ≥ 1.5) in both the AUY922 and 17-
DMAG datasets. Applying these two criteria greatly reduced the number of proteins identified as 
significantly altered in both AUY922 and 17-DMAG datasets (Fig 4.2D). Of both the criteria, 
1.5-fold change criteria were more stringent and resulted in invalidating the majority of the 
protein expression changes. We concluded that applying both criteria to validate changes in 
protein expression was very rigorous and eliminated several proteins from being reported as 
significantly altered. Thus, these criteria allowed us to report only high confidence changes in 
protein expression.  




    A.                                                              B. 
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Figure 4.2: Venn analysis of the effects of statistical criteria on evaluating protein 
expression changes in Jurkat cultures treated with AUY922 vs. 17-DMAG. 
Statistical analysis was performed as described in text. Panel A:  Total number of proteins with 
one-sample T-test p values < 0.05. Panel B: Total number of proteins with Storey FDR corrected 
p-value thresholds of< 0.05. Panel C: Total number of proteins with changes in expression ≥ 1.5 
fold. Panel D: Total number of proteins with changes in expression equal to or greater than 1.5 




 Failure to see selective enrichment of proteins in the unions between the drugs after each 
statistical step suggested that there could be many protein expression changes that were drug-
specific but did not pass the statistical criteria for both the drugs. Therefore, subjecting the data to 
all the statistical tests may have resulted in discarding true protein expression changes. However, 
our raw data suggested that the majority of the proteome is being altered by both inhibitors. 
Nevertheless, we decided to use the more stringent criteria in order to report only high confidence 
changes in protein expression. 
     We next assessed consistency in the direction of the protein expression changes for the 
proteins that pass both criteria in both AUY922 and 17-DMAG datasets. Direction here refers to 
up-regulated or down-regulated. To accomplish this, we divided the proteins showing significant 
alterations in expression from both datasets into up-regulated and down-regulated proteins, and 
then compared the AUY922 and 17-DMAG datasets to look for consistency in expression 
patterns (Fig 4.3). Among the proteins that were identified as significantly altered, the majority 
were down-regulated, as opposed to being up-regulated. This was consistent with our raw 
histograms that indicated that the majority of the proteome is down-regulated by Hsp90 inhibition 
(Fig 3.7 & 3.18, Chapter III). Among 476 proteins down-regulated by either AUY922 or 17-
DMAG, 48% of the responses were common to both inhibitors. Among the 69 proteins up-
regulated by either inhibitor, 46% of the responses were common to both inhibitors (Fig 4.3). 
Thus, we concluded that Hsp90 inhibition leads to more down-regulation than up-regulation. 
Moreover, the direction of the changes was highly similar among drugs, with the majority of the 
proteins down-regulated in the proteome of one drug treated cells also being down-regulated in 
the proteome of cells treated with the other drug. This was also the case for up-regulated proteins. 







Figure 4.3: Comparison of down-regulated and up-regulated proteins expression changes in 
Jurkat cells treated with AUY922 and 17-DMAG 
Panel A: Total number of proteins down-regulated by AUY922 and/or 17-DMAG.  Panel B: 












 In order to visualize the direction and magnitude of the changes induced by AUY922 and 17-
DMAG, the magnitude of changes induced by AUY922 were plotted versus the magnitude of 
changers induced by 17-DMAG. The majority of the protein changes (both significant and non-
significant) were well centered on the diagonal of this plot generating an R
2
 value of 0.681 (Fig 
4.4). This suggested that the protein expression patterns were similar in the Jurkat cells treated 
with either drug.  Moreover, in both AUY922 and 17-DMAG datasets, the majority of the 
significant changes (crosses) were distributed in the lower left hand quadrant of the scatterplot 
(Fig 4.4), suggesting that the majority of the proteins were being down-regulated by both  
inhibitors. 
   There were some significant changes in the upper right hand quadrant in both the datasets, 
indicating proteins that were up-regulated by both the inhibitors. In contrast, there were very few 
changes that were distributed in the lower right hand quadrant and the upper left hand quadrant in 
both the datasets. This suggested that there were very few proteins that were up-regulated by one 
inhibitor but down-regulated by the other inhibitor, and vice versa. In summary, these results 
suggested that: (i) that the inhibitors generated similar effects; and (iii) both the inhibitors cause 










             
Figure 4.4: Comparison of changes in protein expression induced by AUY922, 17-DMAG and 
both AUY922 & 17-DMAG.  
The X-axis represents the log2 values of H/L ratios for individual proteins in the proteomes of 
Jurkat cultures treated with AUY922. The Y-axis represents the log2 values of H/L ratios for 
individual proteins in the proteomes of Jurkat cultures treated with 17-DMAG. The red crosses 
represent the union of AUY922-induced changes & 17-DMAG-induced changes. The grey 
crosses represent the proteins that did not pass both the Storey FDR values < 0.05 and fold 





   To further visualize the inhibitor-specific effects we again plotted the magnitude of changes 
induced by AUY922 versus the magnitude of changes induced by 17-DMAG, but highlighted the 
significant changes induced by AUY922 only (Fig 4.5A). Similarly we plotted 17-DMAG 
induced changes only (Fig 4.5B). Both the plots were largely indistinguishable suggesting that the 
drugs largely shared similar effects. However, there were some changes that appeared to have 
significant alterations in protein expression unique to each drug but failed to survive the rigorous 
statistical tests. This suggested that although the expression changes of these proteins are similar 
between both inhibitors, rigorous statistical tests invalidate them from being detected in both. We 
also plotted the changes induced by both inhibitors (Fig 4.5C). The total number of protein 
changes that are common between both drugs is reduced (c.f. Fig 4.5A, 4.5B vs. 4.5C). This 
reinforced our opinion that the rigorous statistical tests eliminated many proteins with altered 
protein expression. 
   We similarly plotted changes induced by AUY922 versus 17-DMAG after removing all the 
proteins that were not significantly altered by either inhibitor (Fig 4.6A to 4.6C) or that were not 
altered by both inhibitors (Fig 4.7). Eliminating those proteins that were not significantly altered 
improved the R
2 
values from 0.681 to 0.838. Eliminating proteins that were not altered by both 
the drugs improved the R
2
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Figure 4.5: Comparison of the changes in protein expression caused by either AUY922 or 17-
DMAG or both. 
Analysis as described for Figure 4.4. A:  Red crosses are those proteins that are significant in 
AUY922 only. B: Red crosses are the proteins that are significant in 17-DMAG only. C: Red 
crosses are those proteins that are significant in both AUY922 and 17-DMAG. 
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Figure 4.6: Comparison of the changes in protein expression caused by AUY922 vs. 17-DMAG 
after deleting proteins not significant in either or both drugs. 
Analysis as described for Figure 4.4. A: Red crosses represent AUY922 induced changes. B: Red 
crosses represent 17-DMAG induced changes. C: Red crosses represent changes common to both 




   
 
Figure 4.7: Comparison of the changes in protein expression caused by AUY922 & 17-DMAG 
only 
Analysis as described for  Figure 4.4. These plots were constructed after removing those proteins 
that did not pass both criteria in either AUY922 or 17-DMAG or both. Red crosses are drug-






Eliminating proteins whose expression changes were not significant improved the R
2 
fits. This 
suggested that there was high degree of agreement between these proteins altered by both the 
inhibitors, thus indicating that the two inhibitors share common effects. Results also showed that 
the total number of proteins that pass both criteria in both drugs is smaller than the total number 
of proteins that pass both criteria in individual drugs (Fig 4.6B, 4.6C vs. Fig 4.6D and 4.7). Thus, 
we concluded that criteria we used for reporting the proteins with significant alterations in protein 
expression were very stringent and eliminate many drug-specific changes in protein expression. 
Comparison of the number of proteins identified in 5 bioreps versus 3 bioreps 
    To test the effects of the number of biological replicates on our ability to validate protein 
expression changes, we identified the total number of significant protein expression changes in 3 
biological replicate datasets and compared them to the total number of changes identified in 5 
biological datasets by using both ≥ 1.5 fold change and Storey FDR corrected p-value thresholds 
of < 0.05.The total number of changes identified in 3 biological replicate datasets were almost 
45% less than those identified in 5 biological replicate datasets for both AUY922 and 17-DMAG 










Table 4.1: Number of significant protein expression changes identified in 5 biological replicate 




Number of significant 
protein expression 
changes identified in 
AUY922 treated cells 
Number of significant 
protein expression 
changes identified in 
17-DMAG treated 
cells 
Number of significant 
protein expression 
changes common to 
both drugs 
N =5 399 405 260 
N =3 209 252 158 
% Difference 47.7% 37.8% 39%  
 
 












These results indicated that using more biological replicates in SILAC experiments allows for the 
identification of a higher number of significant protein expression changes. The total number of 
protein expression changes we identified in 5 biological replicate datasets were nearly 50% 
higher than the number of protein expression changes identified in 3 biological replicate datasets 
in both AUY922 and 17-DMAG datasets. Thus we concluded that, more the number of biological 
replicates, the greater the power to identify more expression changes and thus more discovery. 
GO analysis 
     To gain insights into the biological processes affected by the AUY922 and 17-DMAG, we 
performed gene ontology (GO) analysis of the proteins that passed both criteria (Storey FDR 
corrected p-value thresholds of< 0.05, and ≥ 1.5 fold change) for each drug. Only the GO terms 
whose B-H corrected values < 0.05 were considered. Both AUY922 and 17-DMAG affected a 
wide variety of functional categories (Tables 4.2 & 4.3). Several processes were down-regulated 
by both AUY922 and 17-DMAG (Table 4.2).Similarly up-regulated categories were also 
common between both the inhibitors (Table 4.3). Indistinguishable GO profiles of AUY922 and 











Table 4.2: Major functional categories down-regulated by either AUY922 or 17-
DMAG. 







GO:0004672 Protein kinase activity 5.0E-12 2.2E-10 
GO:0005524 ATP binding 3.6E-10 1.5E-07 
GO:0032559 Adenyl ribonucleotide binding 6E-10 2.3E-07 
GO:0004674 Protein serine/threonine kinase activity 4.3E-09 3E-06 
GO:0030554 Adenyl nucleotide binding 9E-09 1.95E-06 
GO:0001882 Nucleoside binding 8.2E9 7.5E7 
GO:0001883 Purine nucleoside binding 2.3E8 1.9E6 
GO:0032553 Ribonucleotide binding 8.2E8 1.1E5 
GO:0032555 Purine ribonucleotide binding 8.2E8 1.1E5 
GO:0006468 Protein amino acid phosphorylation 5.4E9 3.2E7 
GO:0017076 Purine nucleotide binding 7.1E7 6E5 
GO:0022403 Cell cycle phase 9.1E8 10E9 
GO:0004693 Cyclin-dependent protein kinase activity 5.4E6 7.1E5 
GO:0016310 Phosphorylation 4.9E7 2.1E5 
GO:0005694 Chromosome 1.8E8 2E6 
GO:0051301 Cell division 7.2E7 4.9E7 
GO:0044427 Chromosomal part 1.1E6 2.1E6 
GO:0004386 Helicase activity 4.2E5 5.71E4 
GO:0007049 Cell cycle 5.4E6 1.6E7 
GO:0006796 Phosphate metabolic process 7.1E6 6.8E5 
GO:0006793 Phosphorus metabolic process 7.1E6 6.8E5 
GO:0005654 Nucleoplasm 1.9E5 1.4E5 
GO:0007067 Mitosis 2.2E5 1.9E4 
GO:0000280 Nuclear division 2.2e5 1.6E4 
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GO:0000279 M phase 2E5 1.3E5 
GO:0031981 Nuclear lumen 7E5 4.7E6 
GO:0000087 M phase of mitotic cell cycle 3.3E5 2.6E4 
GO:0048285 Organelle fission 4E5 3.1E4 
GO:0000166 Nucleotide binding 2.3E4 - 
GO:0022402 Cell cycle process 1.3E4 8.2E6 
GO:0000278 Mitotic cell cycle 1.4E4 6.6E5 
GO:0000775 Chromosome, centromeric region 4.2E4 0.002 
GO:0003677 DNA binding 8.1E4 - 
GO:0006259 DNA metabolic process 2.8E4 - 
GO:0005657 Replication fork 9.3E4 - 
GO:0005643 Nuclear pore 8E4 8.3E4 
GO:0051329 Interphase of mitotic cell cycle 3.9E4 1.9E4 
GO:0051325 Interphase 3.9E4 1.9E4 
GO:0000776 Kinetochore 0.002 - 
GO:0000793 Condensed chromosome - 3.3E5 
GO:0000779 Condensed chromosome, centromeric 
region 
- 9.2E4 
GO:0000777 Condensed chromosome kinetochore - 6.4E4 
GO:0044451 Nucleoplasm part - 9E4 
GO:0000796 Condensin complex - 0.001 








Table 4.3: Major functional categories up-regulated by either AUY922 or 17-DMAG.  
GO Term  Function BH corrected 
values AUY922 
BH corrected values 
17-DMAG 
GO:0006986 response to unfolded protein 2.4E9 1.4E11 
GO:0051789 response to protein stimulus 5.3E9 4.1E11 
GO:0051082 unfolded protein binding 3.5E5 1.5E7 
GO:0010033 response to organic substance 8.2E5 1.8E5 
GO:0006457 protein folding - 7.1E6 
 
 














    In this study, we use the SILAC approach to compare the proteome-wide changes induced by 
two structurally distinct Hsp90 inhibitors, AUY922 and 17-DMAG, in Jurkat leukemia cells.    
AUY922 and 17-DMAG generated conserved proteomics fingerprints with 1190 protein 
expression changes regulated by both the inhibitors. Moreover, nearly all proteins up-regulated by 
one inhibitor were up-regulated by the other inhibitor, and proteins down-regulated by one 
inhibitor were down-regulated by the other inhibitor (with one exception (discussed below)). 
These similar effects indicate a common mechanism of action. 
     The classic cellular responses of Hsp90 inhibition are the degradation of Hsp90-dependent 
client proteins and the induction of chaperones. In our SILAC assays, both AUY922 and 17-
DMAG down-regulated several known Hsp90 clients (kinases, helicases and transcription 
factors). Both the inhibitors up-regulated several members of heat shock protein family. Display 
of classic hallmarks of Hsp90 inhibition by both AUY922 and 17-DMAG in our SILAC data 
strongly validate our mass spectrometry assays.  
    Hsp90 inhibition leads to more down-regulation of the proteome, rather than up-regulation. 
This was evident in both AUY922 and 17-DMAG raw data (Chapter III, Fig 3.8a & 3.9a, and Fig 
3.18a & 3.19a) and after statistical analysis (Fig 4.3). This is also consistent with two recent 
published SILAC studies of Hsp90 inhibition [56, 57].  
    Our results are consistent with previous reports that Hsp90-inhibition mainly down-regulates 
kinases [56, 57] . Both AUY922 and 17-DMAG altered the expression of 30 kinases involved in 
different biological processes. Among the kinases with altered expression, almost all of them 
(except Tyrosine-protein kinase Blk ) were down-regulated by both the inhibitors. Tyrosine-
protein kinase Blk was up-regulated by both AUY922 and 17-DMAG. Thus, the down-regulation 
of several kinases by both the inhibitors strongly validates our mass spectrometry assays. 
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   We report several candidate biomarkers for Hsp90 inhibition in leukemia cells by identifying 
highly confident protein expression changes common to both AUY922 and 17-DMAG. AUY922 
is a drug candidate currently in Phase II clinical trials for the treatment of a wide variety of 
cancers. Thus, these candidate biomarkers can be used to validate the biological activity of 
AUY922 in clinical trials. However, whether the changes we observe in cultured cancer cells are 
preserved in vivo needs to be determined. 
   Additionally, these candidate biomarkers can also be used to validate novel Hsp90 inhibitors. 
Long term goals of our laboratory are to determine whether Hsp90 C-terminal binding agents 
inhibit Hsp90 in vitro in cultured cancer cells. Thus, these biomarkers can be compared to the 
fingerprint of C-terminal binding agents and can be used determine if both classes of inhibitors 
have similar of different mechanisms of action.  
          Our results confirm that MaxQuant is a very reliable proteomics software for analyzing 
SILAC data. The expression changes we identified using MaxQuant were highly similar between 
both Hsp90 inhibitors. Moreover, they were also previously identified in our lab using the label-
free proteomics techniques of spectrum counting. Thus, all these validations give us high 
confidence in the quality of the outcome provided by MaxQuant.  
   However, we did encounter that MaxQuant has certain limitations. It was difficult to compare 
MaxQuant outputs from two different drug treatment experiments, since MaxQuant provides 
slightly different lists of identifiers to the proteins in the two experiments searched in two 
different MaxQuant runs. In the output, MaxQuant provides all the protein identifications that a 
peptide might belong to. The protein identifications that MaxQuant provides along with the major 
protein identification differ for each experiment searched in different MaxQuant searches. 
Therefore, it is difficult to compare two experiments searched in different MaxQuant runs.  
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      As one solution, running all of these files from different experiments in one MaxQuant run 
allows to overcome this problem. However, this approach compromises downstream statistical 
analysis. This results in the reduction of R
2 
values (as shown for AUY922, Table 4.4), thus mis- 
representing reproducibility.  
      To compare our SILAC based studies of Hsp90 inhibition to two recently published SILAC 
based studies of Hsp90 inhibition [56, 57], we attempted to cross reference our list of significant 
protein expression changes to those identified in these two studies. As discussed above, 
MaxQuant output provides multiple accession numbers to the proteins and genes, but this output 
for protein identity is not consistent, and does not exactly match across the different searches / 
studies. By using bio-informatics tools (courtesy of Tyler Warwick, Oklahoma State University) 
to combine protein lists form two different experiments we were only able to match 1/3rd of the 
total proteins from two different experiments. Thus, it was difficult to compare the results from 
the three studies, particularly in light of the large lists of protein expression changes identified. 
Instead, we compared results at the GO level. 
  Comparing GO analysis results from our study to those of Mann [56] and Kuster [57], we 
conclude that the effects of structurally diverse Hsp90 inhibitors are highly conserved across 
different cell lines and among the inhibitors. These conclusions are based on the observation that 
the processes affected in all the three studies were nearly indistinguishable despite the differences 
in the inhibitors, doses, cell lines, and experimental designs used (Tables 4.5 & 4.6). In contrast to 
these two SILAC studies, we did not observe a significant enrichment of GO terms associated 
with DNA repair and damage and proteasome core complex. We speculate that this might be due 
to the high micro-molar concentration of Hsp90 inhibitors used in those studies as opposed to the 
low nano-concentrations used in our study. We speculate that use of high doses of Hsp90 
inhibitors results in apoptosis, thus leading to the up-regulation of proteasomal machinery. Down-  
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Table 4.4:  Comparison of the R
2 
values across the biological replicates in AUY922 
data, by searching AUY922 data alone in MaxQuant versus searching AUY922 data 
along with 17-DMAG data in MaxQuant. 
AUY922 R
2





 values-When searched 
along with 17-DMAG data 
in MaxQuant 
BR1 vs. BR5 0.772 0.535 
BR1 vs. BR4 0.771 0.614 
BR1 vs. BR3 0.833 0.622 
BR1 vs. BR2 0.834 0.653 
BR2 vs. BR5 0.804 0.641 
BR2 vs. BR4 0.844 0.651 
BR2 vs. BR3 0.843 0.668 
BR3 vs. BR5 0.806 0.646 
BR3 vs. BR4 0.842 0.670 
BR4 vs. BR5 0.828 0.661 
 











regulation of DNA damage and DNA repair proteins might also be a cellular consequence of 
apoptosis.   
     We also observed that some of the GO terms from Kuster’s lab data had very high p-values 
compared to p-values from our data and the data from Mann’s lab (Table 4.6). We speculate that 
this might be because, we and Mann’s lab used a 1.5 fold cut off whereas Kuster’s lab did not. 
Using a 1.5 fold change criterion might result in the elimination of several proteins that are 
















Table 4.5: Comparison of the GO terms enriched in our study to the GO terms 
enriched in HeLa cells treated with 50 µM 17-DMAG. 










GO:0006259 DNA metabolic 
process 
1E15 2.8E4 - 
GO:0006986 Response to 
unfolded protein 
8E12 2E9 1.38E11 
GO:0016310 phosphorylation 3E9 4.9E7 2.2E5 
GO:0006796 phosphate metabolic 
process 
2E8 7.1E6 6.8E5 
GO:0006793 phosphorus 
metabolic process 
2E8 7.1E6 6.8E5 
GO:0051789 response to protein 
stimulus 
2E6 5.3E9 4.1E11 
GO:0006468 protein amino acid 
autophosphorlylation 
5E5 5.4E9 3.2E7 
GO:0005694 chromosome 2E4 1.8E6 2E6 
GO:0004672 protein kinase 
activity 
5E13 5E12 2.2E10 




1E9 4.3E9 3E6 
 
Only GO terms common to both the studies were shown. The numbers represent the B-H 






Table 4.6: Comparison of the GO terms enriched in our study to the GO terms 
enriched in the SILAC study where four different cell lines were treated with 5-10 µM 
geldanamycin. 












Four different cancer cell lines treated with 
geldanamycin [57] 




5.0E-12 2.2E-10 6.5E21 2E7 4.5E19 5E11 
GO:0005524 ATP 
binding 













9E-09 1.95E-06 1.4E35 1.4E28 8.2E29 1.3E21 
GO:0001882 Nucleoside 
binding 

















5.4E9 3.2E7 6.4E17 
 




7.1E7 6E5 2.3E37 1E28 1.4E31 5.5E21 
GO:0022403 Cell cycle 
phase 
9.1E8 10E9 2.1E6 0.07 2E12 0.02 
GO:0016310 Phosphoryl
ation 
4.9E7 2.1E5 1.4E16 1.9E5 8E14 2.6E8 
GO:0004386 Helicase 
activity 
4.2E5 5.71E4 4.2E4 0.0003 0.004 - 
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7.1E6 6.8E5 3.7E14 3.9E5 5.8E12 5.3E8 
GO:0005654 Nucleoplas
m 
1.9E5 1.4E5 8.4E7 0.0003 5.1E8 0.01 
GO:0031981 Nuclear 
lumen 
7E5 4.7E6 1.4E8 0.0001 4.3E8 0.03 
GO:0000166 Nucleotide 
binding 
2.3E4 - 1.9E38 1.3E32 4.4E36 1.5E19 
GO:0022402 Cell cycle 
process 
1.3E4 8.2E6 7.3E7 6.5E5 2E16 0.0003 
GO:0000278 Mitotic cell 
cycle 
1.4E4 6.6E5 4E7 4.8E5 1E16 0.002 
GO:0005643 Nuclear 
pore 
8E4 8.3E4 2E4 0.0008 0.0003 0.002 
 
Only GO terms common to both the studies were shown. The numbers represent the B-H 
corrected p-values for the selected GO terms. P values of the GO terms for the data from Wu et 















     To validate the Hsp90 inhibitor-induced changes in protein expression identified in our 
spectrum assays, we compared them to the protein expression changes identified in our SILAC 
assays (Fig 4.8). The majority (87%) of the union of the sets of AUY-induced and 17-DMAG-
induced protein expression changes identified in our spectrum counting assays were also 
identified in our SILAC assays (Fig 4.8). However, in our SILAC assays we identified 1148 
additional changes that were not apparent in the spectrum counting assays (Fig 4.8). Because 
these expression changes were conserved between both Hsp90 inhibitors used for the SILAC 
assays, we are confident that they are real. Failure to detect them by spectrum counting reflects 
the weakness of the spectrum counting technique. In the summary, high degree of similarity 
between spectrum counting results vs. the SILAC results gives us confidence in both the assays. 
However, in terms of the number of significant protein expression changes identified, SILAC is 
















                             
Figure 4.8: Comparison of the significant protein expression changes identified from spectrum 
counting assays to the significant protein expression changes identified from SILAC assays. 
Proteins identified as significantly altered by both AUY922 and 17-DMAG (Student’s T-test p 
values < 0.05) in spectrum counting assays were compared to the proteins identified as 
significantly altered by both AUY922 & 17-DMAG in SILAC assays (One sample T-test 
followed by Storey FDR correction). For this comparison, we selected the proteins with T-test p 
values < 0.05 in spectrum counting assays and the proteins with Storey corrected values < 0.05 in 





Protein folding antagonist AZC potentiates the anti-proliferative effects of AUY922 
in Jurkat leukemia cells. 
Introduction 
    In our spectrum counting and SILAC assays, several chaperones were found to be up-regulated 
by Hsp90 inhibitor AUY922, with a magnitude greater than that of the down-regulated proteins. 
These results suggested that AUY922 causes protein folding burdens. Therefore, we speculated 
the protein folding burdens caused by AUY922 can be enhanced by combinatorial treatments 
with other protein folding antagonists.  
   Thus, we tested the anti-proliferative effects of AUY922 in Jurkat leukemia cells by 
combinatorial treatment with a protein folding antagonist L-azetadine-2-carboxylic acid (AZC). 
AZC is a proline analog that gets incorporated into newly synthesized proteins and leads to 
protein folding burdens by destabilizing proteins [107-110]. We also tested the anti-proliferative 
effects of AUY922 in the presence of another protein folding antagonist, namely tunicamycin. 
Tunicamycin inhibits N-glycosylation of proteins in the endoplasmic reticulum, and causes ER 
protein folding burdens. We further tested whether AUY922, AZC, and tunicamycin share 
conserved mechanisms, by comparing the proteomic fingerprints of cells treated with either of 
these drugs, or combination of AUY922 and AZC, using the Stable Isotope Labeling with Amino 




Materials and Methods 
   Materials used in this study were the same as described in Chapter II and chapter III. Conditions 
used to culture Jurkat cells were described in Chapter II. 
AUY922 and AZC combinatorial drug treatments 
    For treatment with two different drugs, cells were seeded in 96 well plates at a density of 
10,000 cells/100ul/well. After twenty four hours, cells were treated with indicated concentrations 
of the 1
st
 drug or with DMSO. Following drug treatment, cells were incubated at 37°C in a CO2 
incubator. After ten hours of incubation, cells were treated with indicated concentrations of the 
second drug or DMSO. After 38 hours of incubation with 2
nd
 drug, cell viability was determined 
using Cell Titer Aqueous One Solution Cell Proliferation Assay (MTS) reagent as described in 
Chapter II. All experiments were performed in three biological replicates. 
SILAC labeling, drug treatments and preparation of samples for LC-MS/MS analysis 
   Jurkat cultures adapted to SILAC heavy media were treated with IC50 concentrations of either 
AUY922 (15 nM), or AZC (1 mM) or tunicamycin (130 ng/ml) for 48 hours. For control 
experiments Jurkat cultures adapted to SILAC light media were treated with DMSO. After 48 
hours of treatment with drugs or DMSO, cultures were harvested,  lysates from each drug 
treatment were mixed in 1:1 ratio (50 µg of treated and 50 µg of control) and samples were 
prepared for mass spectrometry using methods as described in Chapter III. For AZC and 
AUY922 combinatorial drug treatments, heavy labeled Jurkat cultures were pre-treated with IC50 
concentration of AZC (1 mM), and after 10 hours of AZC treatment, cultures were treated with 
IC50 concentration of AUY922. For control experiments Jurkat cultures adapted to SILAC light 
media were treated with DMSO. After 38 hours of AUY922 treatment cultures were harvested 
and samples were prepared for mass spectrometry using methods as described in Chapter III. 
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MaxQuant searches and statistical analysis 
  Raw MS/MS files from low dose AUY922, AZC, AUY-AZC data were all searched in one 
MaxQuant run. Tunicamycin was searched alone in a separate MaxQuant run. Statistical analysis 
was performed on only the proteins that had intensities in both control and treated samples in all 
three biological replicates. Statistical tests and criteria used were the same as described in Chapter 
IV. 
Results 
    The induction of chaperones and chaperonins (T-complex proteins) identified in our spectrum 
counting assays and SILAC assays suggested that part of the cytotoxic effects of Hsp90 inhibitors 
could be due to a global protein folding burden caused by these inhibitors. Thus, we hypothesized 
that the cytotoxicity of Hsp90 inhibitors could be enhanced by using them in combination with 
other protein folding antagonists.  
         L-Azetadine-2-carboxylic acid (AZC) is a four carbon ring analog of proline (Fig 5.1). 
Incorporation of AZC instead of proline into newly synthesized proteins compromises protein 
folding and induces the synthesis of Hsps in cytoplasm and ER [80, 111] . Thus, we tested the 
anti-proliferative effects of AUY922 in the presence and absence of AZC. The IC50 value for 
AZC for Jurkat cell proliferation was approximately 1 mM (not shown). Pre-treatment of Jurkat 
cells with AZC, followed by treatment with AUY922 reduced cell proliferation when compared 
to either drug alone (Fig 5.2). At high doses of AZC (1.6 mM and above), AZC dominated the 
response. At intermediate doses (0.71 to 1.1 mM), AZC potentiated the effects of AUY922. 
However, at low doses of AZC (0.2 mM – 0.47 mM) both drugs appeared to have synergistic 
effects. This conclusion was based on the observation that at low doses AZC by itself has no 
effects on cell proliferation, AUY922 inhibits proliferation of 20 % of the cells, whereas AZC 
and AUY together inhibit the proliferation of 40 % of the cells. If the drugs had additive effects 
then the percent of cells whose proliferation is inhibited should have been between 0 & 20 %.   
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                                 Proline                                              L-Azetadine-2-carboxylic acid 
Figure 5.1  (Images from Wikipedia commons) 
 
























Figure 5.2-Pretreatment with AZC increases the anti-proliferative effects of AUY922 in 
Jurkat cells. 
Jurkat cultures were pre-treated with indicated concentrations of AZC, followed by AUY922. 
Cell proliferation was measured as described in Methods. One star, T-test p value ≤ 0.05; two 












This indicated that pre-treatment with AZC sensitized Jurkat cells to subsequent treatment with 
Hsp90 inhibitor. This suggests that AZC treatment results in decreased protein stability in the 
cell. As a result, AZC treated cells depend extensively on Hsp90 to support these compromised 
proteins. Inhibiting Hsp90 therefore compromises the proteostasis thus leading to reduced cellular 
proliferation. 
      However, reversing the order of addition of the two drugs (AUY922 treatment followed by 
AZC treatment) did not reduce cellular proliferation as compared to either drug alone (Fig 5.3). 
We speculate that pretreatment with AUY922 results in chaperone induction which offers 
protective response from subsequent unfolded protein burdens induced by AZC treatment. 
      We similarly tested the antiproliferative effects of AUY922 in the presence and absence of 
another protein folding antagonist, tunicamycin. Tunicamycin (Fig 5.4) inhibits glycosylation in 
the endoplasmic reticulum and results in the accumulation of under-glycosylated proteins. This 
leads to ER stress. 
    The IC50 value of tunicamycin for Jurkat cell proliferation was approximately 130 ng/ml (not 
shown). Tunicamycin exhibited a steeper dose curve when compared to AUY, and was similar to 
AUY922 by being cytostatic at higher doses. The percent of cells whose proliferation was 
inhibited by pretreatment of Jurkat cells with tunicamycin, followed by treatment with AUY were 
the same as the percent of cells whose proliferation was inhibited by either drug alone (Fig 5.5). 
Even though both drugs appeared to have slightly additive effects at low doses, these effects were 
not statistically significant. This suggests that tunicamycin compromises ER protein folding but 
not protein folding in the cytoplasm. Therefore pre-treatment with tunicamycin does not cause the 
cells to depend on cytoplasmic Hsp90 to fold these unfolded proteins. Therefore, subsequent 
compromise of Hsp90 function does not grossly reduce the cell proliferation. 







Figure 5.3: Pretreatment with AUY922  does not increase the anti-proliferative effects 
of AZC in Jurkat cells. 
Jurkat cultures were pre-treated with indicated concentrations of AUY922, followed by AZC. 
































Figure 5.5: Pretreatment with TM does not increase the anti-proliferative effects of 
AUY922 in Jurkat cells. 
Jurkat cultures were pre-treated with indicated concentrations of TM, followed by AUY922. Cell 













   To compare the proteome-wide changes induced by AUY922, AZC, a combination of AUY922 
and AZC, or tunicamycin, SILAC equilibrated Jurkat cultures were treated with IC50 doses of 
each drug (See methods). For AZC and AUY922 combinatorial treatments, Jurkat cultures were 
pre-treated with IC50 dose of AZC followed by treatment with IC50 dose of AUY922 after 10 
hours of AZC pre-treatment. 
   To facilitate the bioinformatics comparison of the proteomic fingerprints of all four drug 
treatments, LC-MS/MS files from the AUY922, AZC, and AZC & AUY922 combination 
experiments were searched in a single MaxQuant search, as opposed to searching them in 
individual MaxQuant searches. However, LC-MS/MS raw files from tunicamycin experiment 
were searched individually. Our initial analysis indicated that tunicamycin induced very few 
protein expression changes and therefore, we decided to manually compare tunicamycin induced 
changes to the changes induced by the other three drugs. 
      Before analyzing the effects of the four drugs on Jurkat proteome, we assessed the quality of 
the raw data from all these drug treatments using the same approach as described in Chapter III. 
In all the drug treatments except tunicamycin, reproducibility across the three biological 
replicates was moderate (Table 5.1). The  R
2
 values for AUY922 across the three biological 
replicates ranged from 0.479 to 0.532 (Fig 5.6). The R
2
 values for AZC across the three biological 
replicates ranged from 0.309 to 0.345 (Fig 5.7). The R
2
 values for AZC and AUY922 







Table 5.1:  Comparison of the R
2 
values across the biological replicates in AZC data, by 









 values-When searched 
along with other 
experiments 
in MaxQuant 
BR1 vs. BR2 0.592 0.345 
BR1 vs. BR3 0.592                    0.309 
BR2 vs. BR3 0.667                    0.391 
 
    









Figure 5.6: Reproducibility across the three biological replicates in Jurkat cultures 
treated with 15 nM AUY922. 
Protein expression changes (Log2 ratio H/L) were plotted across the three biological replicates. 
The X-axis and the Y-axis represent fold changes in protein expression. In this figure, AY 








Figure 5.7: Reproducibility across the three biological replicates in Jurkat cultures 
treated with 1 mM AZC. 
Protein expression changes (Log2 ratio H/L) were plotted across the three biological replicates as 












Figure 5.8: Reproducibility across the three biological replicates in Jurkat cultures 
treated with 1 mM AZC followed by 15 nM AUY922. 
Protein expression changes (Log2 ratio H/L) were plotted across the three biological replicates as 





To examine the reasons for these moderate R
2 
values observed across the biological replicates in 
AUY922, AZC, and AZC plus AUY922 combinatorial treatment experiments, the R
2
 values in all 
three experiments obtained from individual MaxQuant searches of each drug treatment 
experiment we compared versus the R
2
 values obtained by searching all three experiments in a 
single MaxQuant search. This revealed that searching the files from all three experiments in one 
MaxQuant search reduced the R
2
 values (Example AZC -Table 5.1). Thus, we concluded that 
moderate R
2 
values observed in AUY922, AZC and combinations of AUY and AZC were not due 
to problems with reproducibility, but because of searching all files in one MaxQuant search. 
  Reproducibility across the three biological replicates in tunicamycin dataset was also low, with 
R
2 
values ranging from 0.215 to 0.278 (Fig 5.9), even though, the Tunicamycin files were 
searched as an individual set in MaxQuant. We speculated that these low R
2 
values were due to 
the drug inducing relatively minor changes in the proteome. 
    Data from all the experiments was normalized using the normalization approach described in 
Chapter III. Normalization minimized variability across the biological replicates (not shown) in 










Figure 5.9: Reproducibility across the three biological replicates in Jurkat cultures 
treated with 130 ng/ml tunicamycin. 
Protein expression changes (Log2 ratio H/L) were plotted across the three biological replicates as 














Figure 5.10: Histograms of average protein expression of all three biological replicates 
in cells treated with AUY922 before and after experiment-level normalization. 
Ratios of H/L intensities from all the three biological replicates were averaged and plotted as 
histograms before (Panel A) and after (Panel B) normalization. The X-axis represents binning of 




















Figure 5.11: Histograms of average protein expression of all three biological replicates 
in cells treated with AZC before and after experiment-level normalization. 
Ratios of H/L intensities from all the three biological replicates were averaged and plotted as 



















                                           
 
 
Figure 5. 12: Histograms of average protein expression of all three biological 
replicates in AUY 922 and AZC combinatorial treatments before and after experiment-
level normalization. 
Ratios of H/L intensities from all the three biological replicates were averaged and plotted as 
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Figure 5.13: Histograms of average protein expression of all three biological replicates 
in tunicamycin dataset before and after experiment-level normalization. 
Ratios of H/L intensities from all the three biological replicates were averaged and plotted as 











   By analyzing H/L ratio histograms from all the four experiments, our raw SILAC ratios implied 
down-regulation across all the proteome (e.g., Fig 5.10). Therefore, we wanted to ensure that the 
heavy and light lysates were mixed in a 1:1 ratio (50 µg of lysate from treated cells & 50 µg from 
control cells). To test this, we averaged all of the light protein intensities and all of the heavy 
protein intensities from each bio-replicate, and compared them (Table 5.2). Results showed that 
the average H/L ratios in AUY922 and tunicamycin experiments were close to 1.0 indicating 
there were no gross problems during the mixing of control and treated samples. Therefore, we 
concluded that the down-regulation bias in AUY922 and tunicamycin experiments was not due to 
improper mixing of heavy and light lysates, and instead reflected large real changes in the Jurkat 
proteome. We also confirmed that the down-regulation bias was not due to improper mixing by 
comparing H/L ratios for a selected list of house-keeping proteins in AUY922 and tunicamycin 
experiments (Table 5.3). The average housekeeping H/L ratios were close to 1.0 in both the 
AUY922 and tunicamycin experiments (Table 5.3). Thus, these results reinforced our conclusions 
that the down-regulation bias was not due to improper mixing. 
 
  However, the average H/L ratios in the AZC and in the AUY922-AZC combinatorial treatment 
experiments implied problems during the mixing of control and treated lysates (Table 5.2). This 
was also evident in the H/L ratios of the actin and several other house-keeping proteins (Table 
5.3) in both experiments.  









Table 5.2: Ratios of the average light and heavy protein intensities from AUY, AZC, AUY and 
AZC combinatorial treatment and tunicamycin experiments. 
 









AUY Low Dose   Biorep-1 
                             Biorep-2 










Tunicamycin       Biorep-1 
                             Biorep-2 










AZC                     Biorep-1 
                             Biorep-2 










AUYplusAZC     Biorep-1 
                             Biorep-2 
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 Table 5.3: Comparison of H/L ratios of house-keeping proteins low dose AUY922, AZC, AUY 

















































Actin, alpha  0.92 0.96 1.1 1.0 1.0 1.08 0.81 0.74 0.94 0.84 0.79 0.78 
Actin, 
cytoplasmic 2 








0.81 0.83 0.95 0.81 0.83 0.87 0.54 0.62 0.70 0.64 0.65 0.72 
Tubulin beta 
chain 
0.88 0.91 0.97 0.90 1.02 1.02 0.65 0.68 0.74 0.65 0.77 0.79 
Tubulin beta-
4A chain 
0.76 0.85 0.87 0.81 0.88 0.94 0.69 0.63 0.70 0.68 0.75 0.65 
Tubulin beta-
4B chain 
0.92 0.89 0.95 0.90 1.0 1.01 0.64 0.68 0.75 0.73 0.71 0.74 




0.87 0.90 0.99 0.91 0.97 1.0 0.71 0.67 0.80 0.72 0.73 0.75 
 
H/L ratios of the house keeping proteins were shown.  BR represents biological replicate. 
 








    To assess whether the down-regulation we observed is due to real changes or due to improper 
mixing of light and heavy lysates, we first speculated that the down-regulation bias observed 
in AZC and AUY and AZC combinatorial treatments might be due to: not identifying 
proteins with AZC containing peptides in the treated samples. To address this, we re-
analyzed the protein expression ratios in AZC-treated cells using MaxQuant, but 
specifying proline to AZC as a variable modification (- 14.00 Da). Out of the total 58,494 
peptides identified, only 1805 peptides had AZC as a modification and the AZC peptides 
were not specific to Heavy samples. However, the majority of the proteome was down-
regulated. Subsequently, we speculated that MaxQuant might not be able to properly 
identify AZC-modified peptides. To address this question, we searched one LC-MS/MS 
file from the AZC experiment using a different search engine (Mascot), specifying AZC 
as a variable modification. We then validated the Mascot results using Scaffold. Of the 
total peptides that Mascot identified, 28 putative AZC peptides were identified. Close 
inspection of each peptide’s MS/MS spectra showed that very few major ion fragments 
could be assigned to contiguous series (ladder) of hypothetical b & y ions. These results 
were consistent with the results obtained from MaxQuant, suggesting that AZC peptides 
were not being detected. Moreover the AZC peptides detected were not specific to treated 
samples. This strongly suggested that AZC peptides were not being identified. Thus, 
because AZC has been shown to be readily incorporated into proteins in cultured cells, 
we concluded that the AZC peptides were not identifiable on the basis of their MS/MS 
fragmentation patterns. 
   Since we were not able to identify AZC peptides by specifying AZC as a variable modification, 
we re-analyzed the protein expression ratios in AZC treated cells using MaxQuant, but by 
specifying proline to AZC as a fixed modification instead of variable modification to effectively 
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eliminate proline containing peptides from the database. Out of the 1818 peptides subsequently 
identified by MaxQuant, only 26 peptides contain proline (as an AZC modification). However, 
the ratios of H/L intensities still implied that the samples were not properly normalized. Thus, we 
concluded that problem is not just due to failure to identify AZC-peptides. 
    Because we could not correct the apparent H vs. L ratio defects by any of the methods above, 
we normalized the results from experiments using cells treated with AZC alone or with the AUY-
AZC combination. To do this, the 3 light channels and the 3 heavy channels were first normalized 
using the experiment-level normalization approach described in Materials and Methods of 
Chapter III (Light intensities were normalized to average light intensities, heavy intensities were 
normalized to average heavy intensities). Following this experiment-level normalization, the light 
intensities and the heavy intensities were normalized to each other as shown below. 
     After performing this correction, the average of ratio of H/L intensities in each of the 
experiments involving AZC was 1.0. This was also evident in the histograms plotted before and 











Correction factor Light intensities = Average intensities (L- channel) / Average intensities (H+L- channel) 
 
Correction factor Heavy intensities = Average intensities (H- channel) / Average intensities (H+L- channel) 
 
Corrected intensity of a protein L-channel = Intensity of a protein L-channel / Correction factor Light 
intensities 
 
Corrected intensity of a protein H-channel = Intensity of a protein H-channel / Correction factor Heavy 
intensities 
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A.                                                                        B. 
       
Figure 5.14: Ratio H/L intensity histograms of all three biological replicates in AZC before 
and after H/L ratio correction. 
Ratios of H/L intensities from all the three bio-reps were plotted before (Panel A) and after (Panel 









A.                                                                        B. 
                   
 
Figure 5.15: Ratio H/L intensity histograms of all three biological replicates in AUY & 
AZC combinatorial treatments before and after H/L ratio correction. 
Ratios of H/L intensities from all the three bio-reps were plotted before (Panel A) and after (Panel 







    In this work, our main objective was to determine the biological basis of the combinatorial 
effects of AUY922 and AZC. We also wanted to determine the biological basis for the absence of 
similar combinatorial effects between AUY922 and tunicamycin. To accomplish this, heavy label 
SILAC-equilibrated individual Jurkat cultures were treated with one of four conditions:  (i) 
AUY922 IC50 dose (15 nM),  hereafter referred to as  “low dose AUY” or “LD AUY922”, (ii)  
AZC at its IC50 dose (1 mM), hereafter referred to as “AZC”, (iii) tunicamycin at its IC50 dose  
(130 ng/ml) hereafter referred to as “tunicamycin” and (iv) a combination of AUY922 at its IC50 
dose (15 nM) plus AZC at its IC50 dose (1 mM) , hereafter referred to as “AUY-AZC”. 
Combinatorial treatments of Jurkat cultures with AUY922 and tunicamycin were not assayed. 
Following drug treatments, proteins were harvested, subjected to  LC-MS/MS, and analyzed by 
MaxQuant software. 
   We wanted to compare the protein expression changes induced by the drugs described above to 
each other,  but  it is difficult to compare data obtained from individual MaxQuant searches (see 
Discussion, Chapter IV). To faciliate drug vs. drug comparisons, the datasets above (the 4 drug 
treatments x 3 biological replicates each) were searched  in a single MaxQuant build. As noted 
below, tunicamycin was omitted. Additionally, three LCMS/MS data files from cells treated with 
high doses of AUY922   (75 nM, representing 5-7X  the IC50, and  hereafter referred to as “high 
dose AUY922” or “HD AUY922”) were analyzed, as were three data files from cells treated with 
high doses of 17-DMAG (150 nM, representing the 5-7X the IC50, hereafter referrred to as “high 
dose 17-DMAG or “HD 17-DMAG”). The later two treatments served as a benchmark for drugs 
sharing a common mechanism of action. Since our preliminary analysis indicated that 
tunicamycin-induced few protein expression changes, tunicamycin data files were searched as a 
separate MaxQuant build (because the small number of changes could be compared manually). 
   To determine if these data sets could be compared to each other, we analyzed the total number 
of protein expression changes identifed in each experiment. Results sohwed that the number of 
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proteins identified in each data set were nearly similar (Fig 5.16). Thus, we concluded that the 
data from the experiments could be compared. 
    Protein expression changes were validated using the statistical tests as described in Materials 
and Methods, using  Storey FDR corrected p-value thresholds of < 0.05 and  fold-change 
threshold of   ≥ 1.5. Protein expression changes that passed both criteria were considered to be 
significant changes. These criteria  identified 200-400 significant changes in cells treated with LD 
AUY, AZC, AUY-AZC , HD AUY and  HD 17-DMAG (Table 5.4). In contrast, tunicamycin 
treated cells showed only 58 significant  protein expression changes (Table 5.4).  
 To define the proteomics fingerprint characterestic of a common drug mechanism, we compared 
proteomes of cells treated with HD AUY922 vs. proteomes of cells treated with HD 17-DMAG. 
For this comparison, three out of five biological replicates from HD AUY and HD 17-DMAG 
were used. A total of 76 % of the changes identified in HD AUY922 treated cells were also 
observed in cells treated with HD 17-DMAG (Fig 5.17, Panel A). Similarly 63% of the changes 
identified in HD 17-DMAG treated cells were conserved in HD AUY treatments (Fig 5.17, Panel 
A). Moreover, the magnitude and direction (up-regulation or down-regulation) of their protein 
expression changes were also conserved  (Fig 5.17, Panel B), generating an R
2
 value of 0.814. 
The majority of the changes were represented in the upper right hand or lower left hand quadrants 
of the scatterplot, and there were few changes in lower right hand quadrant or the upper left hand 
quadrant of the plot comparing changes among both drugs. (Fig 5.17, Panel B). These 
observations defined the characterstics of a proteomics fingerprint for drugs sharing a common 







                                                                                             
Figure 5.16: Total number of proteins detected across 3 biological replicates in the 
proteomes of drug-treated Jurkat cultures. 
The number of biological replicates is denoted by “n”. The n = 3 circle represents the number of 
proteins identified in 3/3 experiments. The n = 2 crescent represents the difference between the 
number of proteins identified in 3/3 experiments vs. the number of proteins identified in 2/3 
experiments. The n = 1 crescent represents the difference between the number of proteins 
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Table 5.4: Effects of statistical tests and criteria for validating protein expression 




Test and/or criteria LD 












(all 3 bio-reps) 
2854 2429 2569 2807 2596 2397 
One sample T-test 
(P < 0.05) 
1115 839 1318 874 1235 1165 
Storey FDR 
correction of one 
sample T-test p 
values (< 0.05) 
1431 1013 1925 991 1775 1670 
Fold change ≥ 1.5 287 338 414 97 299 304 
Storey FDR 
corrected p-value 
thresholds of< 0.05 
and fold change ≥ 
1.5 
















                                           A. 
 
                      B. 
 
 
Figure 5.17: Comparison of the significant changes induced by HD AUY922 vs. HD 
17-DMAG. 
Panel A: Venn analysis of protein expression changes induced by HD AUY922 vs. HD 17-
DMAG. Panel B: Comparison of magnitude of changes induced by both inhibitors. The X –axis 
represents log 2 treated/control (H/L) ratios of proteins in AUY, and the Y-axis represent log 2 
H/L ratios of proteins in 17-DMAG. Red crosses represent significant changes caused by both 
inhibitors, while grey crosses represent insignificant changes in both the inhibitors. 
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   Results from  AUY922 and AZC combinatorial treatments indicated that inhibition of cellular 
proliferation was higher in AUY-AZC treated cells compared to cells treated with each drug 
alone. Thus, we predicted that both drugs have similar effects on the proteome.  Therefore, we 
compared the significant changes identified in each drug. Of the total changes identifed in cells 
treated with LD AUY922, 34% of them were also observed in cells treated with AZC. Of the 
changes identified in cells treated with AZC, 27% of the changes were also observed in cells 
treated with LD AUY922 (Fig 5.18, Panel A). We also plotted the protein expression changes to 
demonstrate their magnitude and direction (up or down-regulation) in both drugs (Fig 5.18, Panel 
B). The R
2 
value for this comparison was 0.298. Moreover, all the proteins showing significant 
changes in both drugs were represented in the upper right hand quadrant or lower left hand 
quadrant. None of the significant changes conserved to both drugs were represented in lower right 
hand quadrant or the upper left hand quadrant. Since 30% of the  protein expression changes were 
conserved between  both drugs, we concluded that the drugs shared similar but not identical 
mechanisms.  
   Because  the inhibition of cell proliferation was higher in Jurkat cells treated with a 
combinations of AUY922 and AZC compared to either drug alone, we predicted that there would 
be more protein expression changes in AUY922-AZC combinatorial treatments compared to 
individual drug treatments. To test this, we compared the changes common to LD AUY- treated 
cells to those observed in cells treated with AUY-AZC. We saw an increase in protein expression 
changes (256 proteins) in cells treated with AUY-AZC compared to cells treated with each drug 
alone. The total changes common to cells treated AUY922-AZC and cells treated with LD 
AUY922 also increased (Fig 5.19, Panel A). We similarly compared changes common to AZC to 
the changes induced by AUY-AZC . The total significant changes common to cells treated with 
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Figure 5.18: Comparison of the significant changes induced by LD AUY922 vs. AZC. 
Panel A: Venn analysis of protein expression changes induced by LD AUY922 vs. AZC. Panel 
B: Comparison of magnitude of changes induced by both inhibitors. The X –axis represents log 2 
treated/control (H/L) ratios of proteins in LD AUY922, and the Y-axis represent log 2 H/L ratios 
of proteins in AZC. Red crosses represent significant changes caused by both inhibitors, while 
grey crosses represent insignificant changes in both the inhibitors. 
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Figure 5.19: Comparison of the significant changes in LD AUY922 vs. LD AUY922 plus AZC, 
and AZC vs. LD AUY922 plus AZC. 
Panel A: Venn analysis of the significant changes induced by LD AUY922 vs. AZC. Panel B: 






Enrichment of protein expression changes in the combinatorial treatments suggested  that some 
protein expression changes were similarly altered by both AUY922 and AZC (c.f. Fig 5.18, Panel 
A vs Fig 5.19, Panels A& B). 
   Since LD AUY922 and AZC appeared to have similar effects on some protein expression 
changes, we speculated that the down-regulated proteins will be more down-regulated in the 
combinatorial treatment compared to the individual drug treatments. Similarly, we speculated that 
the up-regulated chaperones will be more up-regulated in combinatorial treatments, than each 
drug treatment alone, since both the drugs cause protein folding burdens. 
         To test if our speculation was correct, we divided the significant protein expression changes 
into up-regulated and down-regulated. Then we averaged the H/L ratios of all these proteins in 
each drug treatment (LD AUY, AZC, and AUY- AZC combinatorial treatment). Results indicated 
that average H/L ratios for the down-regulated proteins from LD AUY and AUY-AZC were not 
significantly different from each other (Fig 5.20, Panel A). Similarly, the average H/L ratios for 
the up-regulated proteins from AUY922 and AUY- AZC were also not significantly different 
from each other (Fig 5.20, Panel B). Since the average H/L ratios of the down-regulated 
expression changes in LD AUY vs. AUY- AZC were not much different, we concluded that the 
magnitude of down-regulated protein expression changes was not higher in cells treated with 
combinations of AUY922 and AZC relative to those observed in cells treated with LD AUY 
alone.   
Out of all the up-regulated proteins, four proteins showed statistically significant changes in LD 
AUY treated cells vs. AUY-AZC treated cells (Table 5.5). Among these four proteins, three of 
them were more up-regulated in cells treated with LD AUY compared to cells treated with AUY-
AZC. In contrast, the magnitude of up-regulation of Serpin was higher in cells treated with LD 
AUY-AZC when compared to cells treated with LD AUY922. Surprisingly, these results  
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Figure 5.20: Comparison of the average H/L ratios of significant protein expression 
changes in LD AUY922 vs. LD AUY922 plus AZC. 
H/L ratios of the significant protein expression changes in each drug treatment were averaged and 
compared to each other. Panel A: Comparison of the down-regulated expression changes. 





 Table 5.5: Comparison of the H/L ratios of proteins up-regulated in LD AUY922 treated cells  
vs. AUY plus AZC treated cells. 
  LD AUY922 H/L ratio  LD AUY922 plus AZC   
Protein names BR1 BR2 BR3 Average BR1 BR2 BR3 Average 
T-test 
P-values  
Bone marrow stromal 
antigen 2 1.96 2.04 2.22 2.07 1.09 1.47 1.51 1.36 0.017 
Serpin H1 8.55 5.75 4.99 6.43 10.8 12 12.54 11.8 0.023 
Heat shock 70 kDa 
protein 1A/1B 7.3 7.01 7.86 7.39 3.84 4.11 4.30 4.08 0.001 
Docking protein 2 7.89 11.6 9.79 9.76 1.99 1.39 15.98 6.45 0.562 
Heat shock protein 
HSP 90-beta 1.76 1.49 1.53 1.59 1.51 1.5 1.48 1.49 0.367 
Tyrosine-protein 
kinase Blk 2.25 1.8 1.89 1.98 1.4 1.57 1.33 1.43 0.04 
Heat shock protein 
HSP 90-alpha 2.49 2 2.1 2.2 1.69 1.7 1.67 1.69 0.075 
DnaJ homolog 
subfamily B member 
1 4.28 3.45 3.5 3.74 4.37 4.2 4.06 4.21 0.215 
                          
Average 4.56 4.39 4.24 4.4 3.34 3.49 5.36 4.06 
  
Statistical analysis was performed using Student’s T-test, two tailed, unequal variance. P values < 
0.05 were considered significant. 
 









suggested a different model for the combinatorial effects of AUY922 and AZC (see Discussion). 
    Our assays of AUY922 and tunicamycin combinatorial treatments suggested that both drugs 
did not have additive effects on Jurkat cell proliferation (Fig 5.5, Chapter V). Thus, we  predicted 
that the drugs might not share conserved effects on the proteome. To test our prediction, we 
compared the changes induced by LD AUY to the changes induced by tunicamycin to determine 
if the protein expression changes induced by both drugs were conserved. Of the significant 
changes induced by LD AUY, only 3.9% of the changes were observed in cells treated with 
tunicamycin. Among the tunicamycin induced changes, only 12% of the changes were observed 
in cells treated with LD AUY (Fig 5.21). Since only 7 out of total 223 protein expression changes 
were observed between both drugs, we concluded that both the drugs do not have common 
effects. Moreover, these changes might be false discoveries, based on our FDR threshold of 0.05 
(7 out of 172 is 0.04). We did not compare the magnitude of expression changes between both 
drugs because they were searched separately in MaxQaunt, and thus could not be readily 
combined for generating scatterplots. 
   To validate tunicamycin-induced protein expression changes identified in our study, we 
compared them to tunicamycin-induced changes identified by Bull et al [76]. Only changes 
common to both studies were shown (Table 5.6). Up-regulation of ER chaperones in our study is 











Figure 5.21: Comparison of the significant changes in LD AUY922 vs. tunicamycin. 


















Table 5.6: Tunicamycin-induced protein expression changes common between our study and 
study from Bull et al. 
 
 
Protein  Ratio of H/L 
intensities- Our study 
Ratio of H/L intensities 
(Bull et al. 2012 ) 





Endoplasmin 2.30  0.50 
Protein disulfide-
isomerase A3 
1.73  0.85  
Protein disulfide-
isomerase A4 
2.03 0.47  
Protein disulfide-
isomerase A6 
1.79  0.86  
Transferrin receptor 
protein 1 
0.66 1.46  
Thymidylate 
synthase 










0.64  1.46 
Integrin beta-1 0.48  1.56  
 
 
Important Note: Bull et al. used light labeled cells for tunicamycin treatment and heavy labeled 
for control. Therefore H/L ratio > 1 means down-regulated and < 1 means up-regulated.  
 
Bull et.al studied the changes induced by 10 µM tunicamycin in human neuroblastoma cells [76]. 
Values in the right hand column are from Bull et al., Table 1 and supplemental Table 1 and are 












    In this study, AZC potentiates the anti-proliferative effects of AUY922 in cultured Jurkat 
leukemia cells (Fig 5.2). At higher doses, AUY922-AZC combinatorial treatments appear to have 
simple additive effects on cell proliferation. At lower doses, neither drug inhibits cell 
proliferation, but combinations of these doses of AZC and AUY922 inhibit the proliferation of 
cells (Fig 5.2). This hints of drug synergy at low doses. In contrast to AZC, tunicamycin does not 
potentiate AUY922’s anti-proliferative effects (Fig 5.2). 
      AZC, AUY922, and tunicamycin compromise protein folding in different cellular 
compartments, and by different mechanisms. AZC is a proline analog. AZC causes global protein 
folding burdens by getting incorporated into the newly synthesized proteins and destabilizing 
them [107-109].  The Hsp90 inhibitor AUY922 destabilizes client proteins by compromising 
Hsp90 function. Although Hsp90 inhibitors GA , 17AAG and PU-H71  induce ER stress and up-
regulate ER chaperones [73, 74], reports from fluorescence polarization assays indicate that 
AUY922 binds weakly to ER chaperone GRP94 when compared to cytosolic Hsp90 [22]. This 
suggests that AUY922 might be causing protein folding burdens in cytoplasm but not in 
endoplasmic reticulum (ER). Tunicamycin is a bacterial antibiotic that inhibits N-glycosylation of 
proteins in the ER and results in the accumulation of unfolded proteins in the ER.  
      We hypothesize a model for the combinatorial effects of AUY922 and AZC. Both AZC and 
Hsp90 inhibitors destabilize proteins. When cells are treated with both inhibitors, there is large 
destabilization of the cellular proteome. This results in additive or synergistic effects of both 
drugs. 
     We also hypothesize a model for the absence of combinatorial effects between AUY922 and 
tunicamycin. In this model, we hypothesize that the protein folding burdens caused by 
tunicamycin are largely confined to the ER. Whereas results from our SILAC assays and from the 
literature [22], indicate that AUY922 does not significantly induce ER chaperones. This suggests 
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that AUY922 does not cause ER protein folding burdens. Therefore, the absence for 
combinatorial effects of AUY922 and tunicamycin might largely be due to compartmentalization 
of their effects. AUY922 effects might largely be confined to cytoplasm. Whereas tunicamycin 
effects might largely be confined to ER. 
     Results from our SILAC assays were consistent with this model. AUY922 and AZC shared 
some protein targets that were common (Fig 5.18, Panel A). Among these common targets, 
proteins down-regulated by one drug were down-regulated by the other drug and proteins up-
regulated by one drug were up-regulated by the other drug (Fig 5.18, Panel B), thus indicating 
similar effects. Moreover, we see an enrichment of protein expression changes in the 
combinatorial drug treatments, when compared to either drug alone (Fig 5.19 Panels A & B). 
These results are consistent with our model that both AUY922 and AZC compromise protein 
folding and both cause down-regulation of some common proteins. Also consistent with our 
model, tunicamycin and AUY922 do not have combinatorial effects, due to compartmentalization 
of their effects. Similarly, very few protein expression changes were common to AUY922 and 
tunicamycin (Fig 5.21). 
       Based on the model we hypothesized, we expected to see a higher magnitude of down-
regulation of the protein targets common to AUY922 and AZC in cells treated with AUY-AZC 
compared to cells treated with each drug alone. Instead we observed that the magnitude of the 
down-regulation of the common targets was not higher in combinatorial treatments (Fig 5.20, 
Panel A). 
    We also expected to see a higher magnitude of chaperone induction in cells treated with AUY-
AZC compared to cells treated with each drug alone. However, we did not see more chaperone 
induction in the cells treated with AUY-AZC like we expected (Fig 5.20, Panel B). Rather, we 
see that the magnitude of chaperone induction was lower in cells treated with combinations of 
AUY922 and AZC (Fig 5.20, Panel B & Table 5.4). Thus, these results suggested an alternate 
model for the combinatorial effects of AUY922 and AZC. 
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     In this new model, combinatorial effects of AUY-AZC on Jurkat cell proliferation are largely 
due to suppression of chaperone induction, thus depriving cells of chaperone protection. This was 
evident in our assays where most chaperones are less upregulated (with the exception of Serpin 
H1) in the dual drug treatment. This suggests that AZC either destabilizes the chaperones or 
compromises the transcription of these chaperones by compromising the stability of Hsf1. Thus, 
we conclude that the reason for combinatorial effects of AUY922 and AZC are because of a 
compromise in the magnitude of chaperone induction.  
   However, one other possibility exists for the down-regulation of chaperones in AZC treated 
cells. It should be worth noting that in the AZC treated cells, the misfolded proteins (including 
chaperones) might be forming aggregates. These aggregated proteins might be lost in the 
insoluble fractions, thus resulting in low abundance of the aggregated protein in AZC treated 
samples compared to untreated samples. This speculation needs to be further tested to see if 
chaperone down-regulation is due to their destabilization and degradation caused by AZC or due 
to them being lost as insoluble aggregates in AZC treated samples. 
     However, as described above, the magnitude of up-regulation of one chaperone (Serpin H1), 
was higher in cells treated with AUY922 and AZC. SerpinH1 is collagen specific molecular 
chaperone. It is localized in the ER. It is regulated by Hsf1 [112]. Its expression is induced by 
heat shock [113] . It is also up-regulated upon Hsp90 inhibition. Up-regulation of Serpin H1 is 
implicated in the synthesis of collagens [114, 115]. We speculate that the upregulation of 
SerpinH1 in AUY&AZC dual treatments might be to fold the AZC-destabilized-collagen. 
However, this needs to be further explored.  
      Summarizing our results, AZC potentiates AUY922’s effects by decreasing the magnitude of 
chaperone induction. This approach is similar to the use of Hsp90 inhibitors in combinations with 
other inhibitors that compromise chaperone induction. Reikvam et al. [116] showed that Hsp90 
inhibitors in combination with Hsp70 inhibitors have increased anti-proliferative activity in acute 
myeloid leukemia cells [116]. Similarly Matokanovic et al. have shown that the effects of Hsp90 
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inhibitors can be enhanced by using them in combination with siRNA  that silences Hsp70 [117]. 
Thus the results from our study suggest combinatorial approaches for enhancing AUY922’s 




   By analyzing all the work and experimentation we did to study the  proteomics of Hsp90 
inhibition, we offer some thoughts on the experimental strategies we used, spectrum counting vs. 
SILAC, limitations of MaxQuant, experiments that should have been done and future directions. 
    After using spectrum counting and SILAC, we strongly recommend the use of SILAC, 
although it is expensive compared to spectrum counting. Spectrum counting is a relatively weaker 
technique and allows to identify only few hundred drug-induced changes. It is therefore difficult 
to predict the mechanisms of drug action based on these few changes. Whereas, SILAC offers 
better quantitation and allows identification of several thousands of proteins. Thus, by using 
SILAC we can gain insights into drug mechanisms. 
  We also strongly recommend the use of 5 biological replicates instead of three for SILAC 
experiments. Use of 5 biological replicates allows more protein identifications. 
   For comparing protein expression changes, we recommend using one sample T-test offered by 
Perseus, because it is more permissive than other tests and allows for identifying more protein 
expression changes. For multiple tests correction we recommend using BH test if there are no 
massive changes in the proteome. However, if the drug induces massive changes in the proteome, 
we recommend using Storey FDR test. We also suggest that using 1.5 fold change threshold for 
validating protein expression changes eliminates a lot of true protein expression changes and 
should only be used, when wanting to report only highly confident protein expression changes. 
      We also think that a bio-informatics program is needed to combine files generated from two 
different MaxQuant searches. This will be very helpful for comparing the proteomic fingerprints 
of different drugs. This will eliminate the need for searching all the files in a single MaxQuant 
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search, which otherwise compromises the quality of the data. Alternatively, MaxQuant programs 
might be written such that they generate a single protein ID for each protein, so that files from 
different MaxQuant searches can be easily combined. 
        We think that our work would have been better by including some experiments. Our studies 
should have included SILAC comparisons of low-dose 17-DMAG vs. low dose AUY922. Such 
low dose AUY922 vs. low dose 17-DMAG comparisons would have served as a better positive 
control for fingerprints of drugs sharing common mechanisms, rather than high dose AUY922 vs. 
high dose 17-DMAG comparisons. We should also have done proteomics of tunicamycin and 






























Supplemental Table 2.2 (Chapter II): Significant protein expression changes common 
to AUY922, 17-DMAG and radicicol based on spectrum counting assays. 
 
S.No IPI number Gene name Protein name Up/Down 
1 IPI00186290 EEF2 Elongation factor 2 D 
2 IPI00218993 HSPH1 Isoform Beta of Heat shock protein 
105 kDa 
U 
3 IPI00293464 DDB1 DNA damage-binding protein 1 D 
4 IPI00304925 HSPA1A Heat shock 70 kDa protein 1A/1B U 
5 IPI00027493 SLC3A2 Isoform 2 of 4F2 cell-surface antigen 
heavy chain 
U 
6 IPI00011200 PHGDH D-3-phosphoglycerate dehydrogenase U 
7 IPI00031519 DNMT1 Isoform 1 of DNA (cytosine-5)-
methyltransferase 1 
D 
8 IPI00023529 CDK6 Cyclin-dependent kinase 6 D 
9 IPI00015947 DNAJB1 DnaJ homolog subfamily B member 1 U 
10 IPI00026689 CDK1 Cyclin-dependent kinase 1 D 
11 IPI00005614 SPTBN1 Isoform Long of Spectrin beta chain, 
brain 1 
U 
12 IPI00032140 SERPINH1 Serpin H1 U 
13 IPI00377261 FUBP3 Isoform 1 of Far upstream element-
binding protein 3 
U 
14 IPI00002214 KPNA2 Importin subunit alpha-2 D 
15 IPI00382470 HSP90AA1 Isoform 2 of Heat shock protein HSP 
90-alpha 
U 
16 IPI00017617 DDX5 Probable ATP-dependent RNA 
helicase DDX5 
D 
17 IPI00301263 CAD CAD protein D 
18 IPI00010720 CCT5 T-complex protein 1 subunit epsilon U 
19 IPI00329789 ZAP70 Isoform 1 of Tyrosine-protein kinase 
ZAP-70 
D 
20 IPI00797279 UHRF1 E3 ubiquitin-protein ligase UHRF1 
isoform 2 
D 
21 IPI00003865 HSPA8 Isoform 1 of Heat shock cognate 71 
kDa protein 
U 
22 IPI00008524 PABPC1 Isoform 1 of Polyadenylate-binding 
protein 1 
D 
23 IPI00746165 WDR1 Isoform 1 of WD repeat-containing 
protein 1 
U 
24 IPI00550021 RPL3 60S ribosomal protein L3 D 
25 IPI00219005 FKBP4 Peptidyl-prolyl cis-trans isomerase 
FKBP4 
U 
26 IPI00553185 CCT3 T-complex protein 1 subunit gamma U 
27 IPI00220362 HSPE1 10 kDa heat shock protein, 
mitochondrial 
U 
28 IPI00396370 EIF3B Isoform 1 of Eukaryotic translation 
initiation factor 3 subunit B 
D 
29 IPI00020127 RPA1 Replication protein A 70 kDa DNA-
binding subunit 
D 
30 IPI00217975 LMNB1 Lamin-B1 U 
31 IPI00470891 CSDE1 Isoform Long of Cold shock domain-
containing protein E1 
D 





33 IPI00007764 HN1 Isoform 1 of Hematological and 





Supplemental Table 2.3  (Chapter II): Significant protein expression changes common 





IPI number Gene name Protein name Inhibitors Up/Down 
1 IPI00396435 DHX15 Putative pre-mRNA-splicing factor 





2 IPI00290566 TCP1 T-complex protein 1 subunit alpha AUY, 
Radicicol 
U 
3 IPI00001734 PSAT1 Phosphoserine aminotransferase AUY, 
Radicicol 
U 
4 IPI00783097 GARS Glycyl-tRNA synthetase DMAG, 
Radicicol 
U 
5 IPI00013894 STIP1 Stress-induced-phosphoprotein 1 AUY, 
Radicicol 
U 
6 IPI00291097 PML Isoform PML-13 of Protein PML DMAG, 
Radicicol 
U 
7 IPI00456887 HNRNPUL2 Heterogeneous nuclear 
ribonucleoprotein U-like protein 2 
DMAG, AUY U 
8 IPI00456969 DYNC1H1 Cytoplasmic dynein 1 heavy chain 1 DMAG, 
Radicicol 
U 
9 IPI00002459 ANXA6 Annexin A6 AUY, 
Radicicol 
U 





11 IPI00219446 PEBP1 Phosphatidylethanolamine-binding 
protein 1 
DMAG, AUY D 










14 IPI00002966 HSPA4 Heat shock 70 kDa protein 4 DMAG, AUY U 
15 IPI00171903 HNRNPM Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein M 
DMAG, AUY U 
16 IPI00465439 ALDOA Fructose-bisphosphate aldolase A DMAG, 
Radicicol 
D 
17 IPI00302927 CCT4 T-complex protein 1 subunit delta DMAG, AUY U 
18 IPI00016910 EIF3C Eukaryotic translation initiation 
factor 3 subunit C 
DMAG, AUY D 
19 IPI00299524 NCAPD2 Condensin complex subunit 1 DMAG, 
Radicicol 
D 
20 IPI00019848 HCFC1 Isoform 1 of Host cell factor 1 DMAG, 
Radicicol 
D 
21 IPI00010471 LCP1 Plastin-2 AUY, 
Radicicol 
U 




23 IPI00025491 EIF4A1 Eukaryotic initiation factor 4A-I AUY, 
Radicicol 
D 
24 IPI00642238 HP1BP3 Isoform 1 of Heterochromatin 




25 IPI00219156 RPL30 60S ribosomal protein L30 DMAG, AUY D 






27 IPI00395568 PHF6 Isoform 1 of PHD finger protein 6 DMAG, 
Radicicol 
U 
28 IPI00009342 IQGAP1 Ras GTPase-activating-like protein 
IQGAP1 
DMAG, AUY U 
29 IPI00012341  Isoform SRP40-1 of 
Serine/arginine-rich splicing factor 
5 
DMAG, AUY U 
30 IPI00411559 SMC4 Isoform 1 of Structural maintenance 
of chromosomes protein 4 
DMAG, AUY D 
















34 IPI00790342 RPL6 60S ribosomal protein L6 AUY, 
Radicicol 
D 
35 IPI00221088 RPS9 40S ribosomal protein S9 AUY, 
Radicicol 
D 




































Supplemental Table 2.4 (Chapter II): Significant protein expression changes in just one 
inhibitors based on spectrum counting assays. 
 
S.No IPI number Gene name Protein name Inhibitors Up/Down 
1 IPI00027626 CCT6A T-complex protein 1 subunit zeta AUY U 
2 IPI00296337 PRKDC Isoform 1 of DNA-dependent 
protein kinase catalytic subunit 
AUY D 
3 IPI00026781 FASN Fatty acid synthase AUY D 
4 IPI00030706 AHSA1 Activator of 90 kDa heat shock 
protein ATPase homolog 1 
AUY U 
5 IPI00023530 CDK5 Cyclin-dependent kinase 5 AUY D 
6 IPI00184533 USP11 Ubiquitin carboxyl-terminal 
hydrolase 11 
Radicicol U 
7 IPI00000846 CHD4 Isoform 1 of Chromodomain-
helicase-DNA-binding protein 4 
AUY D 
8 IPI00007673 CHCHD2 Coiled-coil-helix-coiled-coil-helix 
domain-containing protein 2, 
mitochondrial 
AUY D 
9 IPI00515097 LCK Isoform 3 of Tyrosine-protein 
kinase Lck 
AUY D 
10 IPI00305833 SMU1 WD40 repeat-containing protein 
SMU1 
DMAG D 
11 IPI00376219 APBB1IP Amyloid beta A4 precursor protein-
binding family B member 1-
interacting protein 
DMAG D 
12 IPI00292894 TSR1 Pre-rRNA-processing protein TSR1 
homolog 
Radicicol D 
13 IPI00479262 EIF4G1 eukaryotic translation initiation 
factor 4 gamma 1 isoform 1 
AUY D 
14 IPI00221108 TYMS Thymidylate synthase AUY D 
15 IPI00012462 EIF2A Eukaryotic translation initiation 
factor 2A 
AUY D 
16 IPI00218245 EVL Isoform 1 of Ena/VASP-like protein Radicicol U 
17 IPI00011696 VAV1 Proto-oncogene vav Radicicol U 
18 IPI00465044 RCC2 Protein RCC2 AUY D 
19 IPI00007928 PRPF8 Pre-mRNA-processing-splicing 
factor 8 
AUY D 
20 IPI00027834 HNRNPL Heterogeneous nuclear 
ribonucleoprotein L 
AUY U 
21 IPI00376317 EDC4 Isoform 1 of Enhancer of mRNA-
decapping protein 4 
AUY D 
22 IPI00007765 HSPA9 Stress-70 protein, mitochondrial DMAG U 
23 IPI00013485 RPS2 40S ribosomal protein S2 DMAG D 
24 IPI00018465 CCT7 T-complex protein 1 subunit eta DMAG U 
25 IPI00257508 DPYSL2 Dihydropyrimidinase-related 
protein 2 
DMAG U 
26 IPI00007074 YARS Tyrosyl-tRNA synthetase, 
cytoplasmic 
DMAG U 
27 IPI00218342 MTHFD1 C-1-tetrahydrofolate synthase, 
cytoplasmic 
Radicicol D 
28 IPI00022462 TFRC Transferrin receptor protein 1 Radicicol D 
29 IPI00299904 MCM7 Isoform 1 of DNA replication 
licensing factor MCM7 
Radicicol D 




31 IPI00027230 HSP90B1 Endoplasmin AUY U 
32 IPI00449049 PARP1 Poly [ADP-ribose] polymerase 1 AUY U 
33 IPI00221354 FUS Isoform Short of RNA-binding 
protein FUS 
DMAG U 
34 IPI00299573 RPL7A 60S ribosomal protein L7a DMAG D 
35 IPI00104050 THRAP3 Thyroid hormone receptor-
associated protein 3 
DMAG U 
36 IPI00291755 NUP210 Isoform 1 of Nuclear pore 
membrane glycoprotein 210 
DMAG U 
37 IPI00025874 DDOST Dolichyl-
diphosphooligosaccharide--protein 
glycosyltransferase subunit 1 
precursor 
AUY U 
38 IPI00215719 RPL18 60S ribosomal protein L18 AUY D 
39 IPI00007797 FABP5 Fatty acid-binding protein, 
epidermal 
DMAG D 
40 IPI00514053 ARCN1 Coatomer subunit delta DMAG U 
41 IPI00177728 CNDP2 Isoform 1 of Cytosolic non-specific 
dipeptidase 
DMAG D 
42 IPI00002520 SHMT2 Serine hydroxymethyltransferase, 
mitochondrial 
DMAG D 
43 IPI00376798 RPL11 Isoform 1 of 60S ribosomal protein 
L11 
DMAG D 
44 IPI00182757 KIAA1967 Isoform 1 of Protein KIAA1967 
(DBC) 
AUY D 
45 IPI00329791 DDX46 Probable ATP-dependent RNA 
helicase DDX46 
AUY D 
46 IPI00007927 SMC2 Isoform 1 of Structural maintenance 
of chromosomes protein 2 
AUY D 
47 IPI00456359 ATXN2L Isoform 1 of Ataxin-2-like protein AUY D 
48 IPI00306043 YTHDF2 Isoform 1 of YTH domain family 
protein 2 
AUY D 
49 IPI00013495 ABCF1 Isoform 2 of ATP-binding cassette 
sub-family F member 1 
AUY D 
50 IPI00293434 SRP14 Signal recognition particle 14 kDa 
protein 
DMAG U 
51 IPI00008986 SLC7A5 Large neutral amino acids 
transporter small subunit 1 
DMAG U 
52 IPI00005198 ILF2 Interleukin enhancer-binding factor 
2 
DMAG U 
53 IPI00012772 RPL8 60S ribosomal protein L8 AUY D 
54 IPI00021290  ATP-citrate synthase DMAG D 
55 IPI00010133 CORO1A Coronin-1A DMAG U 
56 IPI00299000 PA2G4 Proliferation-associated protein 2G4 DMAG D 
57 IPI00012535 DNAJA1 DnaJ homolog subfamily A 
member 1 
Radicicol U 
58 IPI00375441 FUBP1 Isoform 1 of Far upstream element-
binding protein 1 
Radicicol U 
59 IPI00013788 HTATSF1 HIV Tat-specific factor 1 Radicicol U 
60 IPI00396378 HNRNPA2B1 Isoform B1 of Heterogeneous 
nuclear ribonucleoproteins A2/B1 
AUY U 
61 IPI00010740 SFPQ Isoform Long of Splicing factor, 




62 IPI00025091 RPS11 40S ribosomal protein S11 AUY D 
63 IPI00295851 COPB1 Coatomer subunit beta AUY U 
64 IPI00030131  Isoform Beta of Lamina-associated 
polypeptide 2, isoforms 
beta/gamma 
DMAG U 
65 IPI00294879 RANGAP1 Ran GTPase-activating protein 1 DMAG U 
66 IPI00022648 EIF5 Eukaryotic translation initiation 
factor 5 
DMAG U 
67 IPI00012079 EIF4B Eukaryotic translation initiation 
factor 4B 
Radicicol U 
68 IPI00746004 RPS27L 40S ribosomal protein S27-like Radicicol D 
69 IPI00022202  Isoform A of Phosphate carrier 
protein, mitochondrial 
Radicicol U 
70 IPI00024364 TNPO1 Isoform 1 of Transportin-1 Radicicol U 
71 IPI00297579 CBX3 Chromobox protein homolog 3 Radicicol U 
72 IPI00020356  Uncharacterized protein Radicicol U 
73 IPI00027107 TUFM elongation factor Tu, mitochondrial 
precursor 
AUY U 
74 IPI00012074 HNRNPR Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein R 
AUY U 
75 IPI00008529 RPLP2 60S acidic ribosomal protein P2 AUY U 
76 IPI00301503 TRA2B Isoform 1 of Transformer-2 protein 
homolog beta 
AUY U 
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     Abbreviations 
     
     GA-               Geldanamycin 
     Hsp-              Heat shock protein 
     17-DMAG-   17-Dimethylaminoethylamino-17-demethoxygeldanamycin 
     MCM-           Mini chromosome maintenance proteins 
     UPR-             Unfolded protein response 
     HSR-             Heat shock response 
     ERAD-          Endoplasmic reticulum associated protein degradation 
     CID-             Collision induced dissociation 
     ECD-            Electron capture dissociation 
     ETD-            Electron capture dissociation 
     ICAT-           Isotope coded affinity tags 
     IAA-             Iodoacetamide 
     TCEP-          (tris (2-carboxyethyl) phosphine)  
     DTT-            Dithiothreotol 
     ACN-           Acetonitrile 
     TFA-            Trifluoro acetic acid 
     DMSO-        Dimethyl sulfoxide 
     Cdk6-           Cyclin dependent kinase 6 
     IC50-            50% inhibitory concentration 
     SC-              Spectrum counting 
     SILAC-        Stable isotope labeling with amino acids in cell culture 
     H-                Heavy or treated samples 
     L-                 Light or control (DMSO) samples 
     MQ-             MaxQuant 
     FDR-            False discovery rate 
     B-H-            Benjamini Hochberg 
     AZC-           L-azetadine-2-carboxylic acid 
     TM-             Tunicamycin 
     FWHM-       Full width at half maximum height 
     GO-             Gene Ontology     
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T-test p-values, and Storey FDR corrected values of T-test p-values for all drugs in 
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